Psychology Wiki
mNo edit summary
mNo edit summary
Line 1: Line 1:
 
{{ClinPsy}}
 
{{ClinPsy}}
'''Treatment resistant depression''' is [[major depression]] that is resistant to [[[drug therapy]], particularly with [[tricyclic antidepressant drugs]]
+
'''Treatment resistant depression''' is [[major depression]] that is resistant to [[drug therapy]], particularly with [[tricyclic antidepressant drugs]]
   
   

Revision as of 21:16, 29 February 2008

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Clinical: Approaches · Group therapy · Techniques · Types of problem · Areas of specialism · Taxonomies · Therapeutic issues · Modes of delivery · Model translation project · Personal experiences ·


Treatment resistant depression is major depression that is resistant to drug therapy, particularly with tricyclic antidepressant drugs


See also


References

  • Transcranial magnetic stimulation: Potential new treatment for resistant depression. (2007).): Journal of Clinical Psychiatry Vol 68(2) Feb 2007, 315-330.
  • Abbass, A. A. (2006). Intensive short-term dynamic psychotherapy of treatment-resistant depression: A pilot study: Depression and Anxiety Vol 23(7) Nov 2006, 449-452.
  • Abraham, G. (2004). Combined Transcranial Magnetic Stimulation and Right Unilateral Electroconvulsive Therapy in Patients with Treatment-Refractory Depression: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 49(6) Jun 2004, No Pagination Specified.
  • Abraham, G., Milev, R., & Lawson, J. S. (2006). T3 augmentation of SSRI resistant depression: Journal of Affective Disorders Vol 91(2-3) Apr 2006, 211-215.
  • Abraham, G., & O'Brien, S. (2002). Repetitive transcranial magnetic stimulation is useful for maintenance treatment: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 47(4) May 2002, 386.
  • Abramowitz, M. Z., Lichtenberg, P., Marcus, E.-L., & Shapira, B. (1994). Treating a Holocaust survivor without addressing the Holocaust: A case report: Clinical Gerontologist Vol 14(3) 1994, 75-80.
  • Achiffer, F., Stinchfield, Z., & Pascual-Leone, A. (2002). Prediction of clinical response to transcranial magnetic stimulation for depression by baseline lateral visual-field stimulation: Neuropsychiatry, Neuropsychology, & Behavioral Neurology Vol 15(1) Mar 2002, 18-27.
  • Adlersberg, S., Toren, P., Mester, R., Rehavi, M., & et al. (1994). Verapamil is not an antidepressant in patients resistant to tricyclic antidepressants: Clinical Neuropharmacology Vol 17(3) Jun 1994, 294-297.
  • Adli, M., Rush, A. J., Moller, H. J., & Bauer, M. (2003). Algorithms for optimizing the treatment of depression: Making the right decision at the right time: Pharmacopsychiatry Vol 36(Suppl3) Nov 2003, S222-S229.
  • Aguado, J. M. R., & Pinedo, M. A. (2003). Venlafaxine and ECT. A safe and effective combination: Revista de Psiquiatria de la Facultad de Medicina de Barcelona Vol 30(5) Nov-Dec 2003, 234-237.
  • Alexopoulos, G. S., Canuso, C. M., Gharabawi, G. M., Bossie, C. A., Greenspan, A., Turkoz, I., et al. (2008). Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression: American Journal of Geriatric Psychiatry Vol 16(1) Jan 2008, 21-30.
  • Alpert, J. E., Mischoulon, D., Rubenstein, G. E. F., Bottonari, K., Nierenberg, A. A., & Fava, M. (2002). Folinic acid (leucovorin) as an adjunctive treatment for SSRI-refractory depression: Annals of Clinical Psychiatry Vol 14(1) Mar 2002, 33-38.
  • Alvarez, E., Perez-Sola, V., Perez-Blanco, J., Queralto, J. M., & et al. (1997). Predicting outcome of lithium added to antidepressants in resistant depression: Journal of Affective Disorders Vol 42(2-3) Feb 1997, 179-186.
  • Amchin, J., & Albano, D. (1997). Clinical considerations in managing nausea associated with venlafaxine: Journal of Clinical Psychopharmacology Vol 17(6) Dec 1997, 489-490.
  • Amiaz, R., Stein, O., Dannon, P. N., Grunhaus, L., & Schreiber, S. (1999). Resolution of treatment-refractory depression with naltrexone augmentation of paroxetine: A case report: Psychopharmacology Vol 143(4) Apr 1999, 433-434.
  • Amsterdam, J. D. (2004). A 36-year-old Man With a History of Non-response to Multiple Medications: Trials of various pharmacologic combinations may be necessary to find the correct treatment in some cases of resistant depression: Psychiatric Annals Vol 34(3) Mar 2004, 180-181.
  • Amsterdam, J. D. (2006). Monoamine Oxidase Inhibitor Therapy in Severe and Resistant Depression: Psychiatric Annals Vol 36(9) Sep 2006, 607-613.
  • Amsterdam, J. D., & Chopra, M. (2001). Monoamine oxidase inhibitors revisited: Psychiatric Annals Vol 31(6) Jun 2001, 361-370.
  • Amsterdam, J. D., & Hornig-Rohan, M. (1996). Treatment algorithms in treatment-resistant depression: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 371-386.
  • Amsterdam, J. D., Maislin, G., & Potter, L. (1994). Fluoxetine efficacy in treatment resistant depression: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 18(2) Mar 1994, 243-261.
  • Amsterdam, J. D., Rosenzweig, M., & Mozley, P. D. (1994). Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketoconazole. Oxford, England: John Wiley & Sons.
  • Amsterdam, J. D., & Shults, J. (2005). MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study: Journal of Affective Disorders Vol 89(1-3) Dec 2005, 183-188.
  • Anand, A., Malison, R., McDougle, C. J., & Price, L. H. (1995). Antiglucocorticoid treatment of refractory depression with ketoconazole: A case report: Biological Psychiatry Vol 37(5) Mar 1995, 338-340.
  • Ananth, J. (1998). Treatment-resistant depression: Psychotherapy and Psychosomatics Vol 67(2) Mar-Apr 1998, 61-70.
  • Anghelescu, I., & Muller-Forell, W. (2005). Bilateral Exophthalmos and Depression: Not Always Endocrine Ophthalmopathy: Journal of Neuropsychiatry & Clinical Neurosciences Vol 17(3) Sum 2005, 427.
  • Anghelescu, I., & Urbanek, C. (2005). Tadalafil in a Patient With Treatment-Resistant Depression and Antidepressant Polypharmacy: Journal of Clinical Psychopharmacology Vol 25(2) Apr 2005, 191-192.
  • Antai-Otong, D. (2007). The art of prescribing: Perspectives in Psychiatric Care Vol 43(3) Jul 2007, 142-145.
  • Appelberg, B. G., Syvalahti, E. K., Koskinen, T. E., Mehtonen, O.-P., Muhonen, T. T., & Naukkarinen, H. H. (2001). Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study: Journal of Clinical Psychiatry Vol 62(6) Jun 2001, 448-452.
  • Apter, J. T., Kushner, S. F., & Woolfolk, R. L. (1994). Bupropion/nortriptyline combination for refractory depression: Annals of Clinical Psychiatry Vol 6(4) Dec 1994, 255-258.
  • Argyropoulos, S. V., Wheeler, A., & Nutt, D. J. (1999). A case of reversal of treatment-resistant depression after almost 30 years of symptoms: International Journal of Psychiatry in Clinical Practice Vol 3(4) Dec 1999, 289-291.
  • Armitage, R., Husain, M., Hoffmann, R., & Rush, A. J. (2003). The effects of vagus nerve stimulation on sleep EEG in depression: A preliminary report: Journal of Psychosomatic Research Vol 54(5) May 2003, 475-482.
  • Aronson, R., Offman, H. J., Joffe, R. T., & Naylor, C. D. (1996). Triiodothyronine augmentation in the treatment of refractory depression: A meta-analysis: Archives of General Psychiatry Vol 53(9) Sep 1996, 842-848.
  • Avery, D. H., Claypoole, K., Robinson, L., Neumaier, J. F., Dunner, D. L., Scheele, L., et al. (1999). Repetitive transcranial magnetic stimulation in the treatment of medication-resistant depression: Preliminary data: Journal of Nervous and Mental Disease Vol 187(2) Feb 1999, 114-117.
  • Avery, D. H., Holtzheimer, P. E., III, Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., et al. (2006). A Controlled Study of Repetitive Transcranial Magnetic Stimulation in Medication-Resistant Major Depression: Biological Psychiatry Vol 59(2) Jan 2006, 187-194.
  • Axford, S. L. (1994). Case report 1: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 367.
  • Bader, C. D., & Dunner, D. L. (2007). Antidepressant-induced hypomania in treatment-resistant depression: Journal of Psychiatric Practice Vol 13(4) Jul 2007, 233-237.
  • Bailine, S. H., Sciano, A., & Millman, B. (2005). ECT Treatment of a Patient With Aortic Aneurysms: Journal of ECT Vol 21(3) Sep 2005, 178-179.
  • Baker, M., & Turner, M. (2000). Use of ECT after maxillofacial repair: Journal of ECT Vol 16(4) Dec 2000, 421-422.
  • Bakish, D. (1994). Potentiation of fluoxetine by buspirone and trazodone in refractory depression. Oxford, England: John Wiley & Sons.
  • Baldwin, R. C. (1996). Refractory depression in late life: A review of treatment options: Reviews in Clinical Gerontology Vol 6(4) Nov 1996, 343-348.
  • Baldwin, R. C., & Simpson, S. (1997). Treatment resistant depression in the elderly: A review of its conceptualisation, management and relationship to organic brain disease: Journal of Affective Disorders Vol 46(3) Dec 1997, 163-173.
  • Bannan, N. (2005). Multimodal therapy of treatment resistant depression: A study and analysis: International Journal of Psychiatry in Medicine Vol 35(1) 2005, 27-39.
  • Baptista Leal, C. E., Mendes Miguel, L., & Machado Avilla, V. (1992). Refractory depression: Clinical study in four patients: Jornal Brasileiro de Psiquiatria Vol 41(5) Jun 1992, 213-218.
  • Barak, Y., Stein, D., Levine, J., Ring, A., & et al. (1996). Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: An open trial: Human Psychopharmacology: Clinical and Experimental Vol 11(6) Nov-Dec 1996, 463-467.
  • Barak, Y., Suholitsky, H., & Noy, S. (1996). Moclobemide treatment of resistant depression in a patient with vascular dementia: Human Psychopharmacology: Clinical and Experimental Vol 11(1) Jan-Feb 1996, 67-68.
  • Barbee, J. G., Conrad, E. J., & Jamhour, N. J. (2004). Aripiprazole Augmentation in Treatment-Resistant Depression: Annals of Clinical Psychiatry Vol 16(4) Oct-Dec 2004, 189-194.
  • Barbee, J. G., Conrad, E. J., & Jamhour, N. J. (2004). The Effectiveness of Olanzapine, Risperidone, Quetiapine, and Ziprasidone as Augmentation Agents in Treatment-Resistant Major Depressive Disorder: Journal of Clinical Psychiatry Vol 65(7) Jul 2004, 975-981.
  • Barbee, J. G., & Jamhour, N. J. (2002). Lamotrigine as an augmentation agent in treatment-resistant depression: Journal of Clinical Psychiatry Vol 63(8) Aug 2002, 737-741.
  • Barbosa, L., Berk, M., & Vorster, M. (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes: Journal of Clinical Psychiatry Vol 64(4) Apr 2003, 403-407.
  • Bares, M., Brunovsky, M., Kopecek, M., Stopkova, P., Novak, T., Kozeny, J., et al. (2007). Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: A pilot study: Journal of Psychiatric Research Vol 41(3-4) Apr-Jun 2007, 319-325.
  • Barker, W. A., Scott, J., & Eccleston, D. (1987). The Newcastle chronic depression study: Results of a treatment regime: International Clinical Psychopharmacology Vol 2(3) Jul 1987, 261-272.
  • Barowsky, J., & Schwartz, T. L. (2006). An evidence-based approach to augmentation and combination strategies for treatment-resistant depression: Psychiatry Vol 3(7) Jul 2006, 42-59.
  • Basgul, E., & Celiker, V. (2004). Anaesthesia in Electroconvulsive Therapy: Turk Psikiyatri Dergisi Vol 15(3) 2004, 225-235.
  • Bauer, M., Bschor, T., Kunz, D., Berghofer, A., Strohle, A., & Muller-Oerlinghausen, B. (2000). Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression: American Journal of Psychiatry Vol 157(9) Sep 2000, 1429-1435.
  • Bauer, M., Bschor, T., Kunz, D., Berghofer, A., Strohler, A., & Muller-Oerlinghausen, B. (2001). Dr. Bauer and colleagues reply: American Journal of Psychiatry Vol 158(8) Aug 2001, 1338-1339.
  • Bauer, M., & Dopfmer, S. (1999). Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies: Journal of Clinical Psychopharmacology Vol 19(5) Oct 1999, 427-434.
  • Bauer, M., & Dopfmer, S. (2000). Correction by authors to "Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies." Journal of Clinical Psychopharmacology Vol 20(2) Apr 2000, 287.
  • Bauer, M., Forsthoff, A., Baethge, C., Adli, M., Berghofer, A., Dopfmer, S., et al. (2003). Lithium augmentation therapy in refractory depression - Update 2002: European Archives of Psychiatry and Clinical Neuroscience Vol 253(3) Jun 2003, 132-139.
  • Bauer, M. E., Papadopoulos, A., Poon, L., Perks, P., Lightman, S. L., Checkley, S., et al. (2002). Dexamethasone-induced effects on lymphocyte distribution and expression of adhesion molecules in treatment-resistant depression: Psychiatry Research Vol 113(1-2) Dec 2002, 1-15.
  • Bauer, M. E., Papadopoulos, A., Poon, L., Perks, P., Lightman, S. L., Checkley, S., et al. (2003). Altered glucocorticoid immunoregulation in treatment resistant depression: Psychoneuroendocrinology Vol 28(1) Jan 2003, 49-65.
  • Baumann, P., Broly, F., Kosel, M., & Eap, C. B. (1998). Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping: Pharmacopsychiatry Vol 31(2) Mar 1998, 72.
  • Baune, B. T., Caliskan, S., & Todder, D. (2007). Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression: Human Psychopharmacology: Clinical and Experimental Vol 22(1) Jan 2007, 1-9.
  • Bech, P., Olsen, L. R., Jarlov, N., Hammer, M., Schutze, T., & Breum, L. (1999). A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors: Acta Psychiatrica Scandinavica Vol 100(1) Jul 1999, 76-78.
  • Bechter, K., Herzog, S., Schreiner, V., Brinkmeier, H., Aulkemeyer, P., Weber, F., et al. (2000). Borna disease virus-related therapy-resistant depression improved after cerebrospinal fluid filtration: Journal of Psychiatric Research Vol 34(6) Nov-Dec 2000, 393-396.
  • Bell, C., Wilson, S., & Nutt, D. J. (1998). Pindolol augmentation of sertraline in resistant depression and its effect on sleep: Journal of Psychopharmacology Vol 12(1) 1998, 105-107.
  • Benazzi, F. (1997). Resistant depression associated with lupus erythematosus and steroid therapy: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 42(5) Jun 1997, 530-531.
  • Benazzi, F. (2002). Fluoxetine and olanzapine for resistant depression: American Journal of Psychiatry Vol 159(1) Jan 2002, 155.
  • Benazzi, F. (2004). Testing Early-Onset Chronic Atypical Depression Subtype: Neuropsychopharmacology Vol 29(2) Feb 2004, 440-441.
  • Benjelloun, G., Blandin, K., & Fossati, P. (2004). Valpromide, Valproic acid and removal of hail intestine in the treatment of a chronic depression: A case report: L'Encephale Vol 30(4) Jul-Aug 2004, 400-403.
  • Berigan, T. R., Harazin, J., & Williams, H. L. (1995). Use of flumazenil in conjunction with electroconvulsive therapy: American Journal of Psychiatry Vol 152(6) Jun 1995, 957.
  • Berlim, M. T., & Turecki, G. (2007). Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 52(1) Jan 2007, 46-54.
  • Berlim, M. T., & Turecki, G. (2007). What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials: European Neuropsychopharmacology Vol 17(11) Nov 2007, 696-707.
  • Berman, R. M., Narasimhan, M., Sanacora, G., Miano, A. P., Hoffman, R. E., Hu, X. S., et al. (2000). A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression: Biological Psychiatry Vol 47(4) Feb 2000, 332-337.
  • Bertschy, G., Ragama-Pardos, E., Ait-Ameur, A., Muscionico, M., Favre, S., & Roth, L. (2003). Lithium augmentation in venlafaxine non-responders: An open study: European Psychiatry Vol 18(6) Oct 2003, 314-317.
  • Bird, D., Haddad, P. M., & Dursun, S. M. (2002). An overview of the definition and management of treatment-resistant depression: Klinik Psikofarmakoloji Bulteni Vol 12(2) Jun 2002, 92-101.
  • Birkenhager, T. K., van den Broek, W. W., Fekkes, D., Mulder, P. G., Moleman, P., & Bruijn, J. A. (2007). Lithium addition in antidepressant-resistant depression: Effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 31(5) Jun 2007, 1084-1088.
  • Birkenhager, T. K., Vegt, M., & Nolen, W. A. (1997). An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression: Pharmacopsychiatry Vol 30(1) Jan 1997, 23-26.
  • Birmaher, B., Waterman, G. S., Ryan, N. D., Perel, J., McNabb, J., Balach, L., et al. (1998). Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression: Journal of the American Academy of Child & Adolescent Psychiatry Vol 37(5) May 1998, 527-535.
  • Blackwell, M. (1994). Case report 2: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 367.
  • Blanco-Jerez, C., Robles, D. E., Gilaberte, A., & Blanco, C. (1996). MAOI-carbamazepine combination and statistical power: Journal of Clinical Psychiatry Vol 57(7) Jul 1996, 311-312.
  • Blier, P. (2006). Medication Combination and Augmentation Strategies in the Treatment of Major Depression. Washington, DC: American Psychiatric Publishing, Inc.
  • Blier, P. (2006). The Sequenced Treatment Alternatives to Relieve Depression (STAR*D): A First Look at the Initial Pharmacotherapy Results: Clinical Neuropsychiatry: Journal of Treatment Evaluation Vol 3(4) Aug 2006, 265-267.
  • Blier, P., & Bergeron, R. (1998). The use of pindolol to potentiate antidepressant medication: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 16-25.
  • Bodani, M., Sheehan, B., & Philpot, M. (1999). The use of dexamethasone in elderly patients with antidepressant-resistant depressive illness: Journal of Psychopharmacology Vol 13(2) 1999, 196-197.
  • Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995). Buprenorphine treatment of refractory depression: Journal of Clinical Psychopharmacology Vol 15(1) Feb 1995, 49-57.
  • Bodner, R. A., Lynch, T., Lewis, L., & Kahn, D. (1995). Serotonin syndrome: Neurology Vol 45(2) Feb 1995, 219-223.
  • Bondolfi, G., Lissner, C., Kosel, M., Eap, C. B., & Baumann, P. (2000). Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences: International Journal of Neuropsychopharmacology Vol 3(1) Mar 2000, 55-60.
  • Bonin, B., Bertschy, G., Baumann, P., & Francois, T. (1996). Fluoxetine and tricyclic antidepressants: Short-term tolerance of the association: L'Encephale Vol 22(3) May-Jun 1996, 221-227.
  • Bonne, O., Krausz, Y., Gorfine, M., Karger, H., & et al. (1996). Cerebral hypoperfusion in medication resistant, depressed patients assessed by Tc99m HMPAO SPECT: Journal of Affective Disorders Vol 41(3) Dec 1996, 163-171.
  • Bonner, D., & Howard, R. (1995). Clinical characteristics of resistant depression in the elderly: International Journal of Geriatric Psychiatry Vol 10(12) Dec 1995, 1023-1027.
  • Bonner, D., & Howard, R. (1995). Treatment resistant depression in the elderly: International Journal of Geriatric Psychiatry Vol 10(4) Apr 1995, 259-264.
  • Bonner, D., & Howard, R. (1995). Treatment-resistant depression in the elderly: International Psychogeriatrics Vol 7(Suppl) 1995, 83-94.
  • Borckardt, J. J., Anderson, B., Kozel, F. A., Nahas, Z., Smith, A. R., Thomas, K. J., et al. (2006). Acute and long-term VNS effects on pain perception in a case of treatment-resistant depression: Neurocase Vol 12(4) Aug 2006, 216-220.
  • Boutros, N. N., Gueorguieva, R., Hoffman, R. E., Oren, D. A., Feingold, A., & Berman, R. M. (2002). Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression: Psychiatry Research Vol 113(3) Dec 2002, 245-254.
  • Brent, D. A., & Birmaher, B. (2006). Treatment-Resistant Depression in Adolescents: Recognition and Management: Child and Adolescent Psychiatric Clinics of North America Vol 15(4) Oct 2006, 1015-1034.
  • Brochier, T., Pascalis, J. G., & Loo, H. (1993). Lithium in refractory depression: L'Encephale Vol 19(5) Sep-Oct 1993, 553-564.
  • Brotman, M. A., Fergus, E. L., Post, R. M., & Leverich, G. S. (2000). High exposure to neuroleptics in bipolar patients: A retrospective review: Journal of Clinical Psychiatry Vol 61(1) Jan 2000, 68-72.
  • Bschor, T., Baethge, C., Adli, M., Eichmann, U., Ising, M., Uhr, M., et al. (2003). Association between responses to lithium augmentation and the combined DEX/CRH test in major depressive disorder: Journal of Psychiatric Research Vol 37(2) Mar-Apr 2003, 135-143.
  • Bschor, T., & Bauer, M. (2004). Is Successful Lithium Augmentation Limited to Serotonergic Antidepressants? : Journal of Clinical Psychopharmacology Vol 24(2) Apr 2004, 240-241.
  • Bschor, T., Canata, B., Muller-Oerlinghausen, B., & Bauer, M. (2001). Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression: Journal of Affective Disorders Vol 64(2-3) May 2001, 261-265.
  • Bschor, T., Lewitzka, U., Sasse, J., Adli, M., Koberle, U., & Bauer, M. (2003). Lithium augmentation in treatment-resistant depression: Clinical evidence, serotonergic and endocrine mechanisms: Pharmacopsychiatry Vol 36(Suppl3) Nov 2003, S230-S234.
  • Burke, M. J., & Husain, M. M. (2006). Concomitant Use of Vagus Nerve Stimulation and Electroconvulsive Therapy for Treatment-resistant Depression: Journal of ECT Vol 22(3) Sep 2006, 218-222.
  • Burrows, G. D., Norman, T. R., & Judd, F. K. (1994). Definition and differential diagnosis of treatment-resistant depression: International Clinical Psychopharmacology Vol 9(Suppl 2) Jun 1994, 5-10.
  • Caetano, D., & Caetano, S. C. (2005). Olanzapine in the treatment of resistant depression: Australian and New Zealand Journal of Psychiatry Vol 39(1-2) Jan 2005, 108-109.
  • Camprubi, M. E., & Puri, B. K. (1995). The treatment of refractory depression using paroxetine with lithium augmentation: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 19(3) May 1995, 515-517.
  • Cappiello, A., McDougle, C. J., Malison, R. T., Heninger, G. R., & et al. (1995). Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study: Biological Psychiatry Vol 38(11) Dec 1995, 765-767.
  • Carpenter, L. L. (2006). Neurostimulation in resistant depression: Journal of Psychopharmacology Vol 20(3, Suppl) May 2006, 35-40.
  • Carpenter, L. L., Jocic, Z., Hall, J. M., Rasmussen, S. A., & Price, L. H. (1999). Mirtazapine augmentation in the treatment of refractory depression: Journal of Clinical Psychiatry Vol 60(1) Jan 1999, 45-49.
  • Carpenter, L. L., Milosavljevic, N., Schecter, J. M., Tyrka, A. R., & Price, L. H. (2005). Augmentation With Open-Label Atomoxetine for Partial or Nonresponse to Antidepressants: Journal of Clinical Psychiatry Vol 66(10) Oct 2005, 1234-1238.
  • Carson, S. W. (1996). Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders: Psychopharmacology Bulletin Vol 32(4) 1996, 555-568.
  • Caso, S. T. F. (2002). Use of Reboxetine in Obsessive Disorders: Preliminary Findings: Psiquiatria Vol 18(1) Jan-Apr 2002, 57-60.
  • Cassano, P., Lattanzi, L., Soldani, F., Navari, S., Battistini, G., Gemignani, A., et al. (2004). Pramipexole in Treatment-Resistant Depression: An Extended Follow-Up: Depression and Anxiety Vol 20(3) 2004, 131-138.
  • Catafau, A. M., Perez, V., Gironell, A., Martin, J. C., Kulisevsky, J., Estorch, M., et al. (2001). SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients: A pilot study: Psychiatry Research: Neuroimaging Vol 106(3) May 2001, 151-160.
  • Cavanagh, J., Patterson, J., Pimlott, S., Dewar, D., Eersels, J., Dempsey, M. F., et al. (2006). Serotonin Transporter Residual Availability During Long-Term Antidepressant Therapy Does Not Differentiate Responder and Nonresponder Unipolar Patients: Biological Psychiatry Vol 59(4) Feb 2006, 301-308.
  • Ceskova, E. (2002). Vagus nerve stimulation: Ceska a Slovenska Psychiatrie Vol 98(5) 2002, 283-286.
  • Chandragiri, S. S. (1997). "Resistance to antidepressant medications and short-term clinical response to ECT": Comment: American Journal of Psychiatry Vol 154(5) May 1997, 721-722.
  • Christensen, R. C., & McCrary, S. V. (1995). Treatment refusal by an elderly man suffering intensely from treatment-resistant depression: Psychiatric Services Vol 46(2) Feb 1995, 181-183.
  • Clifford, E. M., Whale, R., Sharp, T., & Cohen, P. J. (1999). Effect of penbutolol on neuroendocrine responses to busipirone and mood in SSRI-refractory patients: A preliminary study: Human Psychopharmacology: Clinical and Experimental Vol 14(4) Jun 1999, 273-277.
  • Cohen, C. I., Amassian, V. E., Akande, B., & Maccabee, P. J. (2003). The efficacy and safety of bilateral rTMS in medication-resistant depression: Journal of Clinical Psychiatry Vol 64(5) May 2003, 613-614.
  • Cole, A. J., Brittlebank, A. D., & Scott, J. (1994). The role of cognitive therapy in refractory depression. Oxford, England: John Wiley & Sons.
  • Colombo, C. (2000). Problems and new perspective on the pharmacological treatment of depression: Psichiatria e Psicoterapia Analitica Vol 19(4) Dec 2000, 337-344.
  • Conca, A., Konig, P., & Hausmann, A. (2000). Transcranial magnetic stimulation induces 'pseudoabsence seizure.' Acta Psychiatrica Scandinavica Vol 101(3) Mar 2000, 246-248.
  • Conca, A., Peschina, W., Konig, P., Fritzsche, H., & Hausmann, A. (2002). Effect of chronic repetitive transcranial magnetic stimulation on regional cerebral blood flow and regional cerebral glucose uptake in drug treatment-resistant depressives: A brief report: Neuropsychobiology Vol 45(1) Jan 2002, 27-31.
  • Conus, P., Bondolfi, G., Eap, C. B., Macciardi, F., & et al. (1996). Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient: Pharmacopsychiatry Vol 29(3) May 1996, 108-110.
  • Conway, C. R., Sheline, Y. I., Chibnall, J. T., George, M. S., Fletcher, J. W., & Mintun, M. A. (2006). Cerebral blood flow changes during vagus nerve stimulation for depression: Psychiatry Research: Neuroimaging Vol 146(2) Mar 2006, 179-184.
  • Cook, I. A., Leuchter, A. F., Morgan, M. L., Stubbeman, W., Siegman, B., & Abrams, M. (2005). Changes in prefrontal activity characterize clinical response in SSRI nonresponders: A pilot study: Journal of Psychiatric Research Vol 39(5) Sep 2005, 461-466.
  • Corcoran, C. D., Thomas, P., Phillips, J., & O'Keane, V. (2006). Vagus nerve stimulation in chronic treatment-resistant depression: Preliminary findings of an open-label study: British Journal of Psychiatry Vol 189(3) Sep 2006, 282-283.
  • Corey-Lisle, P. K., Birnbaum, H. G., Greenberg, P. E., Marynchenko, M. B., & Claxton, A. J. (2002). Identification of a claims data "signature" and economic consequences for treatment-resistant depression: Journal of Clinical Psychiatry Vol 63(8) Aug 2002, 717-726.
  • Corrubte, E., & Guelfi, J. D. (2000). Does increasing dose improve efficacy in patients with poor antidepressant response: A review: Acta Psychiatrica Scandinavica Vol 101(5) May 2000, 343-348.
  • Corya, S. A., Anderson, S. W., Detke, H. C., Kelly, L. S., Van Campen, L. E., Sanger, T. M., et al. (2003). Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study: Journal of Clinical Psychiatry Vol 64(11) Nov 2003, 1349-1356.
  • Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006). A randomized, double-blind comparison of olanzapine/Fluoxetine combination, olanzapine, fluoxetine, and Venlafaxine in treatment-resistant depression: Depression and Anxiety Vol 23(6) 2006, 364-372.
  • Coryell, W. (2000). Augmentation strategies for inadequate antidepressant response: A review of placebo-controlled studies: Annals of Clinical Psychiatry Vol 12(3) Sep 2000, 141-145.
  • Cowen, P. J. (1994). The effect of tryptophan on brain 5-HT function: A review: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 371-376.
  • Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, J., et al. (2002). The impact of treatment-resistant depression on health care utilization and costs: Journal of Clinical Psychiatry Vol 63(11) Nov 2002, 963-971.
  • Curtin, F., Berney, P., & Kaufmann, C. (2002). Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms: Journal of Psychopharmacology Vol 16(3) Sep 2002, 271-272.
  • Dalery, J., Dagens-Lafont, V., & De Bodinat, C. (1997). Efficacy of tianeptine in the long-term treatment of unipolar major recurrent depressions: L'Encephale Vol 23(1) Jan-Feb 1997, 56-64.
  • Dalery, J., Dagens-Lafont, V., & de Bodinat, C. (2001). Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression: Human Psychopharmacology: Clinical and Experimental Vol 16(Suppl1) Jan 2001, S39-S47.
  • Dalton, E. J., Rotondi, D., Levitan, R. D., Kennedy, S. H., & Brown, G. M. (2000). Use of slow-release melatonin in treatment-resistant depression: Journal of Psychiatry & Neuroscience Vol 25(1) Jan 2000, 48-52.
  • Daniels, S. (2000). Drug treatment for resistant depression: British Journal of Psychiatry Vol 176 Apr 2000, 398.
  • Dannon, P. N., & Grunhaus, L. (2001). Effect of electroconvulsive therapy in repetitive transcranial magnetic stimulation non-responder MDD patients: A preliminary study: International Journal of Neuropsychopharmacology Vol 4(3) Sep 2001, 265-268.
  • Das, P. P., Sharan, P., Grover, S., & Behera, A. (2007). Parathyroid adenoma presenting as bipolar affective disorder: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 48(6) Nov-Dec 2007, 532-533.
  • Dassa, D., Kaladjian, A., Azorin, J. M., & Giudicelli, S. (1993). Clozapine in the treatment of psychotic refractory depression: British Journal of Psychiatry Vol 163 Dec 1993, 822-824.
  • David, M. M., Owen, J. A., Abraham, G., Delva, N. J., Southmayd, S. E., Wooltorton, E., et al. (2000). Thyroid function and response to 48-hour sleep deprivation in treatment resistant depressed patients: Biological Psychiatry Vol 48(4) Aug 2000, 323-326.
  • De Lely, A. A., Van Den Broek, W. W., Mulder, P. G. H., Birkenhager, T. K., & Bruijn, J. A. (2005). Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy: Tijdschrift voor Psychiatrie Vol 47(6) 2005, 351-358.
  • de Montigny, C. (1994). Lithium addition in refractory depression. Oxford, England: John Wiley & Sons.
  • de Montigny, C. (1994). Lithium addition in treatment-resistant depression: International Clinical Psychopharmacology Vol 9(Suppl 2) Jun 1994, 31-35.
  • de Montigny, C., Silverstone, P. H., Debonnel, G., Blier, P., & Bakish, D. (1999). Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial: Journal of Clinical Psychopharmacology Vol 19(5) Oct 1999, 401-406.
  • DeBattista, C. (2006). Augmentation and combination strategies for depression: Journal of Psychopharmacology Vol 20(3, Suppl) May 2006, 11-18.
  • DeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Schatzberg, A. F. (2003). A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants: Journal of Clinical Psychopharmacology Vol 23(1) Feb 2003, 27-30.
  • deGruy, F. V., III. (2006). A Note on the Partnership Between Psychiatry and Primary Care: American Journal of Psychiatry Vol 163(9) Sep 2006, 1487-1489.
  • Dejonge, P., Honig, A., Van Melle, J. P., Schene, A. H., Kuyper, A. M. G., Tulner, D., et al. (2007). Nonresponse to treatment for depression following myocardial infarction: Association with subsequent cardiac events: American Journal of Psychiatry Vol 164(9) Sep 2007, 1371-1378.
  • Detweiler, M. B., & Trinkle, D. B. (2003). Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: A case report: Journal of Clinical Psychiatry Vol 64(7) Jul 2003, 851-852.
  • Deutschman, D. A., & Deutschman, D. H. (2007). High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: A case series: Journal of Clinical Psychopharmacology Vol 27(5) Oct 2007, 513-514.
  • Devarajan, S., Ali, J., & Dursun, S. M. (2006). Quetiapine plus SSRI in treatment-resistant depression: Possible mechanisms: Psychopharmacology Vol 185(3) Apr 2006, 402-403.
  • Devarajan, S., & Dursun, S. M. (2005). Olanzapine plus venlafaxine in treatment-resistant depression: Journal of Psychopharmacology Vol 19(4) Jul 2005, 434-435.
  • Dewan, M. J., & Pies, R. W. (2001). The difficult-to-treat patient with depression. Washington, DC: American Psychiatric Publishing, Inc.
  • Dewan, V. (2000). "Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians": Comment: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 45(9) Nov 2000, 844.
  • Dietrich, D., & Emrich, H. M. (1998). The use of anticonvulsants to augment antidepressant medication: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 51-59.
  • Dilbaz, N., Sengul, C., Okay, T., Bayam, G., & Turkoglu, A. (2005). The combined treatment of venlafaxine and ECT in treatment-resistant depressive patients: International Journal of Psychiatry in Clinical Practice Vol 9(1) Mar 2005, 55-59.
  • Dinan, T. G. (1993). Lithium augmentation in sertraline-resistant depression: A preliminary doseesponse study: Acta Psychiatrica Scandinavica Vol 88(4) Oct 1993, 300-301.
  • Dinan, T. G. (1993). Lithium augmentation in sertraline-resistant depression: A preliminary dose-response study: Acta Psychiatrica Scandinavica Vol 88(4) Oct 1993, 300-301.
  • Dinan, T. G. (1993). A rational approach to the non-responding depressed patient: International Clinical Psychopharmacology Vol 8(4) Win 1993, 221-223.
  • Dinan, T. G., Lavelle, E., Cooney, J., Burnett, F., & et al. (1997). Dexamethasone augmentation in treatment-resistant depression: Acta Psychiatrica Scandinavica Vol 95(1) Jan 1997, 58-61.
  • do Prado-Lima, P. A. S., & Bacaltchuck, J. (2002). Topiramate in treatment-resistant depression and binge-eating disorder: Bipolar Disorders Vol 4(4) 2002, 271-273.
  • Dodd, S., Horgan, D., Malhi, G. S., & Berk, M. (2005). To combine or not to combine? A literature review of antidepressant combination therapy: Journal of Affective Disorders Vol 89(1-3) Dec 2005, 1-11.
  • Dording, C. M. (2000). Antidepressant augmentation and combinations: Psychiatric Clinics of North America Vol 23(4) Dec 2000, 743-755.
  • Dougherty, D. D., & Rauch, S. L. (2007). Somatic Therapies for Treatment-Resistant Depression: New Neurotherapeutic Interventions: Psychiatric Clinics of North America Vol 30(1) Mar 2007, 31-37.
  • Dufresne, R. L. (1996). Issues in polypharmacotherapy: Focus on major depression: Psychopharmacology Bulletin Vol 32(4) 1996, 547-553.
  • Dunner, D. L. (2005). Treatment-Resistant Depression: An Overview of the Problem: Primary Psychiatry Vol 12(2) Feb 2005, 27-29.
  • Dunner, D. L., Amsterdam, J. D., Shelton, R. C., Loebel, A., & Romano, S. J. (2007). Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study: Journal of Clinical Psychiatry Vol 68(7) Jul 2007, 1071-1077.
  • Dunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., et al. (2006). Prospective, Long-Term, Multicenter Study of the Naturalistic Outcomes of Patients With Treatment-Resistant Depression: Journal of Clinical Psychiatry Vol 67(5) May 2006, 688-695.
  • Dursun, S. M., & Devarajan, S. (2001). Accelerated Weight Loss After Treating Refractory Depression With Fluoxetine Plus Topiramate: Possible Mechanisms of Action? : The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 46(3) Apr 2001, 287-288.
  • Dursun, S. M., & Devarajan, S. (2001). Reboxetine plus citaolpram for refractory depression not responding to venlafaxine: Possible mechanisms: Psychopharmacology Vol 153(4) Feb 2001, 497-498.
  • Dursun, S. M., Devarajan, S., & Kutcher, S. (2001). The "Dalhousie serotonin cocktail' for treatment-resistant major depressive disorder: Journal of Psychopharmacology Vol 15(2) 2001, 136-138.
  • Dyck, M. J. (1994). Treatment-resistant depression: A critique of current approaches: Australian and New Zealand Journal of Psychiatry Vol 28(1) Mar 1994, 34-41.
  • Early, T. S. (2003). Low dose, lack of power not a test of sevoflurane burst suppression therapy: Journal of ECT Vol 19(2) Jun 2003, 122.
  • Ebert, D., Albert, R., May, A., Stosiek, I., & et al. (1995). Combined SSRI-RIMA treatment in refractory depression: Safety data and efficacy: Psychopharmacology Vol 119(3) Jun 1995, 342-344.
  • Ehnvall, A., Sjogren, M., Zachrisson, O. C., & Agren, H. (2004). HPA axis activation determined by the CRN challenge test in patients with few versus multiple episodes of treatment-refractory depression: European Archives of Psychiatry and Clinical Neuroscience Vol 254(6) 2004, 349-355.
  • Ehnvall, A., Sjogren, M., Zachrisson, O. C. G., & Agren, H. (2003). Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness: Journal of Affective Disorders Vol 74(2) Apr 2003, 185-189.
  • Ellison, J. M., & Harney, P. A. (2000). Treatment-resistant depression and the collaborative treatment relationship: Journal of Psychotherapy Practice & Research Vol 9(1) Win 2000, 7-17.
  • Enns, M. W. (1999). Re: Predictors of outcome in electroconvulsive therapy: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 44(9) Nov 1999, 921-922.
  • Epstein, C. M., Evatt, M. L., Funk, A., Girard-Siqueira, L., Lupei, N., Slaughter, L., et al. (2007). An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease: Clinical Neurophysiology Vol 118(10) Oct 2007, 2189-2194.
  • Epstein, C. M., Figiel, G. S., McDonald, W. M., Amazon-Leece, J., & Figiel, L. (1998). Rapid rate transcranial magnetic stimulation in young and middle-aged refractory depressed patients: Psychiatric Annals Vol 28(1) Jan 1998, 36-39.
  • Eschweiler, G. W., Vonthein, R., Bode, R., Huell, M., Conca, A., Peters, O., et al. (2007). Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): A short-term randomised controlled trial in pharmaco-resistant major depression: Journal of Affective Disorders Vol 101(1-3) Aug 2007, 149-157.
  • Evins, A. E., Demopulos, C., Nierenberg, A., Culhane, M. A., Eisner, L., & Sachs, G. (2006). A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania: Bipolar Disorders Vol 8(1) Feb 2006, 75-80.
  • Faedda, G. L., Tondo, L., & Baldessarini, R. J. (2001). Lithium discontinuation: Uncovering latent bipolar disorder? : American Journal of Psychiatry Vol 158(8) Aug 2001, 1337-1338.
  • Falkai, P. (1999). Mirtazapine: Other indications: Journal of Clinical Psychiatry Vol 60(Suppl 17) 1999, 36-40.
  • Farah, A., & Colenda, C. C. (1995). Combination ECT and antidepressant therapy: American Journal of Geriatric Psychiatry Vol 3(4) Fal 1995, 356-357.
  • Farmer, C. (1998). The psychodramatic treatment of depression. Florence, KY: Taylor & Frances/Routledge.
  • Fava, G. A., Savron, G., Grandi, S., & Rafanelli, C. (1997). Cognitive-behavioral management of drug-resistant major depressive disorder: Journal of Clinical Psychiatry Vol 58(6) Jun 1997, 278-282.
  • Fava, M. (2000). Management of nonresponse and intolerance: Switching strategies: Journal of Clinical Psychiatry Vol 61(Suppl 2) 2000, 10-12.
  • Fava, M. (2000). New approaches to the treatment of refractory depression: Journal of Clinical Psychiatry Vol 61(Suppl) 2000, 26-32.
  • Fava, M. (2001). Augmentation and combination strategies in treatment-resistant depression: Journal of Clinical Psychiatry Vol 62(Suppl18) 2001, 4-11.
  • Fava, M., & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistant depression: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 179-200.
  • Fava, M., Kaji, J., & Davidson, K. (1996). Pharmacologic strategies for treatment-resistant major depression. New York, NY: Guilford Press.
  • Fava, M., Papakostas, G. I., Petersen, T., Mahal, Y., Quitkin, F., Stewart, J., et al. (2003). Switching to bupropion in fluoxetine-resistant major depressive disorder: Annals of Clinical Psychiatry Vol 15(1) Mar 2003, 17-22.
  • Fava, M., Rosenbaum, J. F., McGrath, P. J., Quitkin, F. M., & et al. (1995). "Lithium or desipramine augmentation of fluoxetine treatment": Reply: American Journal of Psychiatry Vol 152(10) Oct 1995, 1539.
  • Fava, M., Rosenbaum, J. F., McGrath, P. J., Stewart, J. W., & et al. (1994). Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study: American Journal of Psychiatry Vol 151(9) Sep 1994, 1372-1374.
  • Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report: American Journal of Psychiatry Vol 163(7) Jul 2006, 1161-1172.
  • Fawcett, J. (2003). Treatment Resistance--the Focus of Psychiatry: Psychiatric Annals Vol 33(12) Dec 2003, 761-765.
  • Fawcett, J. (2005). Lessons from Treatment-resistant Depression: Psychiatric Annals Vol 35(12) Dec 2005, 949-950.
  • Fawcett, J. (2006). A 55-year-old Man With Long-term Refractory Depression: Psychiatric Annals Vol 36(6) Jun 2006, 384-386.
  • Feijo de Mello, M. (1999). Mirtazapine effectiveness in a patient with refractory psychotic depression: International Journal of Psychiatry in Clinical Practice Vol 3(2) Jun 1999, 141-142.
  • Ferguson, J., Cunningham, L., Merideth, C., Apter, J., & et al. (1994). Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder: Annals of Clinical Psychiatry Vol 6(3) Sep 1994, 153-160.
  • Fink, M. (2006). Interseizure EEG Slowing after ECT is not NCSE: Pharmacopsychiatry Vol 39(3) May 2006, 119.
  • Fischer, P., Tauscher, J., Kufferle, B., & Kasper, S. (1998). Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression: International Clinical Psychopharmacology Vol 13(2) Mar 1998, 83-86.
  • Fitzgerald, P. B., Benitez, J., Castella, A. d., Daskalakis, Z. J., Brown, T. L., & Kulkarni, J. (2006). A Randomized, Controlled Trial of Sequential Bilateral Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: American Journal of Psychiatry Vol 163(1) Jan 2006, 88-94.
  • Fitzgerald, P. B., Brown, T. L., Marston, N. A. U., Daskalakis, Z. J., de Castella, A., & Kulkarni, J. (2003). Transcranial magnetic stimulation in the treatment of depression: A double-blind, placebo-controlled trial: Archives of General Psychiatry Vol 60(10) Oct 2003, 1002-1008.
  • Fitzgerald, P. B., Huntsman, S., Gunewardene, R., Kulkarni, J., & Daskalakis, Z. J. (2006). A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression: International Journal of Neuropsychopharmacology Vol 9(6) Dec 2006, 655-666.
  • Fitzgerald, P. B., Sritharan, A., Daskalakis, Z. J., de Castella, A. R., Kulkarni, J., & Egan, G. (2007). A functional magnetic resonance imaging study of the effects of low frequency right prefrontal transcranial magnetic stimulation in depression: Journal of Clinical Psychopharmacology Vol 27(5) Oct 2007, 488-492.
  • Fleck, M. P., & Horwath, E. (2005). Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice: Psychiatric Services Vol 56(8) Aug 2005, 1005-1011.
  • Flint, A. J. (1995). Augmentation strategies in geriatric depression: International Journal of Geriatric Psychiatry Vol 10(2) Feb 1995, 137-146.
  • Flint, A. J., & Rifat, S. L. (1994). A prospective study of lithium augmentation in antidepressant-resistant geriatric depression: Journal of Clinical Psychopharmacology Vol 14(5) Oct 1994, 353-356.
  • Flint, A. J., & Rifat, S. L. (1996). The effect of sequential antidepressant treatment on geriatric depression: Journal of Affective Disorders 36(3-4) Jan 1996, 95-105.
  • Flint, A. J., & Rifat, S. L. (2001). Nonresponse to first-line pharmacotherapy may predict relapse and recurrence of remitted geriatric depression: Depression and Anxiety Vol 13(3) 2001, 125-131.
  • Folkerts, H. W., Michael, N., Tolle, R., Schonauer, K., Mucke, S., & Schulze-Monking, H. (1997). Electroconvulsive therapy vs. paroxetine in treatment-resistant depression: A randomized study: Acta Psychiatrica Scandinavica Vol 96(5) Nov 1997, 334-342.
  • Francis, A. (2005). ECT and aortic aneurysm: Journal of ECT Vol 21(4) Dec 2005, 254.
  • Franco-Bronson, K. (1996). The management of treatment-resistant depression in the medically ill: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 329-350.
  • Fraser, A. R. (2000). Antidepressant choice to minimise treatment resistance: British Journal of Psychiatry Vol 176 May 2000, 493-494.
  • Fujita, A., Nakaaki, S., Segawa, K., Azuma, H., Sato, K., Arahata, K., et al. (2006). Memory, Attention, and Executive Functions Before and After Sine and Pulse Wave Electroconvulsive Therapies for Treatment-Resistant Major Depression: Journal of ECT Vol 22(2) Jun 2006, 107-112.
  • Gabriel, A. (2006). Lamotrigine adjunctive treatment in resistant unipolar depression: An open, descriptive study: Depression and Anxiety Vol 23(8) 2006, 485-488.
  • Gangadhar, B. N. (2000). "Transcranial magnetic stimulation induces 'pseudoabsence seizure:"' Comment: Acta Psychiatrica Scandinavica Vol 101(3) Mar 2000, 248-249.
  • Gangadhar, B. N., & Bolwig, T. G. (2000). ECT: A different look at prescription: Acta Psychiatrica Scandinavica Vol 102(6) Dec 2000, 399-400.
  • Garcia-Toro, M., Mayol, A., Arnillas, H., Capllonch, I., Ibarra, O., Crespi, M., et al. (2001). Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression: Journal of Affective Disorders Vol 64(2-3) May 2001, 271-275.
  • Garcia-Toro, M., Romera, M., Gonzalez, A., lbanez, P., Garcia, A., Socias, L., et al. (2004). 12-Hour Burst-suppression Anesthesia Does Not Relieve Medication-resistant Major Depression: Journal of ECT Vol 20(1) 2004, 53-54.
  • Garcia-Toro, M., Salva, J., Daumal, J., Andres, J., Romera, M., Lafau, O., et al. (2006). High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression: Psychiatry Research: Neuroimaging Vol 146(1) Jan 2006, 53-57.
  • Garcia-Toro, M., Segura, C., Gonzalez, A., Perello, J., Valdivia, J., Salazar, R., et al. (2001). Inefficacy of burst-suppression anesthesia in medication-resistant major depression: A controlled trial: Journal of ECT Vol 17(4) Dec 2001, 284-288.
  • Garriock, H. A., Allen, J. J. B., Delgado, P., Nahaz, Z., Kling, M. A., Carpenter, L., et al. (2005). Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance: Molecular Psychiatry Vol 10(11) Nov 2005, 976-977.
  • Gash, A. J., Chhabra, S., & Eccleston, D. (1995). Lithium augmentation in a case of renal impairment: Risk vs. benefit: Journal of Affective Disorders 34(1) Apr 1995, 51-53.
  • Gaynes, B. N., Davis, L., Rush, A. J., Trivedi, M., Fava, M., & Wisniewski, S. R. (2005). The Aims and Design of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study: Primary Psychiatry Vol 12(2) Feb 2005, 36-41.
  • Geller, B., Todd, R. D., Luby, J., & Botteron, K. N. (1996). Treatment-resistant depression in children and adolescents: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 253-267.
  • George, M. S., Nahas, Z., Li, X., Anderson, B., Molnar, C., Kose, S., et al. (2005). Current status of daily repetitive transcranial magnetic stimulation for the treatment of depression: Primary Psychiatry Vol 12(10) Oct 2005, 51-58.
  • George, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., et al. (2005). A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression: Biological Psychiatry Vol 58(5) Sep 2005, 364-373.
  • George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Nahas, Z., Lisanby, S. H., et al. (2000). Vagus nerve stimulation: A potential therapy for resistant depression? : Psychiatric Clinics of North America Vol 23(4) Dec 2000, 757-783.
  • George, T., Theodoros, M. T., Chiu, E., Krapivensky, N., Hokin, A., & Tiller, J. W. G. (1999). An open study of sertraline in patients with major depression who failed to respond to moclobemide: Australian and New Zealand Journal of Psychiatry Vol 33(6) Dec 1999, 889-895.
  • Ghadirian, A. M., Engelsmann, F., Dhar, V., Filipini, D., & et al. (1995). The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment: Biological Psychiatry Vol 37(6) Mar 1995, 369-375.
  • Gilliatt, E. P., & Reynolds, P. E. (1995). Occult central hypothyroidism in depression: A case study: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 40(7) Sep 1995, 429-430.
  • Ginsberg, D. L. (2005). Adjunctive Ropinirole for Treatment-Resistant Depression: Primary Psychiatry Vol 12(8) Aug 2005, 26-27.
  • Ginsberg, D. L. (2005). Aripiprazole Augmentation for Treatment-Resistant Depression: Primary Psychiatry Vol 12(6) Jun 2005, 26-27.
  • Ginsberg, D. L. (2006). Low dose oral selegiline for severe refractory depression: Primary Psychiatry Vol 13(1) Jan 2006, 26-27.
  • Glassman, A. H. (1994). Antidepressant plasma levels revisted: International Clinical Psychopharmacology Vol 9(Suppl 2) Jun 1994, 25-30.
  • Goldstein, G., Fava, M., Culler, M., Fisher, A., Rickels, K., Lydiard, R. B., et al. (2000). Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression: Biological Psychiatry Vol 48(1) Jul 2000, 65-69.
  • Gonul, A. S., Akdeniz, F., Donat, O., & Vahip, S. (2003). Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: Four cases: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 27(5) Aug 2003, 889-891.
  • Gonul, A. S., Doksat, K., Eker, C., & Eker, O. D. (2005). Managing Treatment-Resistant Depression: Focusing on Increasing Serotonergic Transmission. Hauppauge, NY: Nova Biomedical Books.
  • Gonzalez-Pinto, A., Gutierrez, M., Gonzalez, N., Elizagarate, E., Perez de Heredia, J. L., & Mico, J. A. (2002). Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression: Journal of Neuropsychiatry & Clinical Neurosciences Vol 14(2) Spr 2002, 206-209.
  • Gorczyca, I., Zwolinski, P., Roszkowski, M., & Niemcewicz, S. (2006). Vagus nerve stimulation in severe, treatment-resistent depression: Psychiatria Polska Vol 40(6) 2006, 1137-1142.
  • Gorman, J. M. (1999). Mirtazapine: Clinical overview: Journal of Clinical Psychiatry Vol 60(Suppl 17) 1999, 9-13.
  • Gorman, J. M., & Hatterer, J. A. (1994). The role of thyroid hormone in refractory depression. Oxford, England: John Wiley & Sons.
  • Gotto, J., & Rapaport, M. H. (2005). Treatment Options in Treatment-Resistant Depression: Primary Psychiatry Vol 12(2) Feb 2005, 42-50.
  • Granato, P., Parquet, J. P., & Goudemand, M. (1994). Midazolam improvement of severe mood disorder: European Psychiatry Vol 9(6) 1994, 318.
  • Greden, J. F. (2001). The burden of disease for treatment-resistant depression: Journal of Clinical Psychiatry Vol 62(Suppl16) 2001, 26-31.
  • Gregson, J. (1999). Venlafaxine and paroxetine in treatment-resistant depression: British Journal of Psychiatry Vol 175 Dec 1999, 591.
  • Grof, P., Joffe, R., Kennedy, S. H., Persad, E., & et al. (1993). An open study of oral flesinoxan, a 5-HT-sub(1A ) receptor agonist, in treatment-resistant depression: International Clinical Psychopharmacology Vol 8(3) Fal 1993, 167-172.
  • Gruber, A. J., Hudson, J. I., & Pope, H. G., Jr. (1996). The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine: Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 351-369.
  • Grunhaus, L., Schreiber, S., Dolberg, O. T., Polak, D., & Dannon, P. N. (2003). A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression: Biological Psychiatry Vol 53(4) Feb 2003, 324-331.
  • Gutierrez, M. A., Stimmel, G. L., & Aiso, J. Y. (2003). Venlafaxine: A 2003 Update: Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy Vol 25(8) Aug 2003, 2138-2154.
  • Gutierrez, R. L., McKercher, R., Galea, J., & Jamison, K. L. (2005). Lamotrigine Augmentation Strategy for Patients with Treatment-Resistant Depression: CNS Spectrums Vol 10(10) Oct 2005, 800-805.
  • Habrat, E. (1994). Life events in endogenous depression and drug resistance: Psychiatria Polska Vol 28(4) Jul-Aug 1994, 467-477.
  • Hammond, D. C. (2000). Neurofeedback treatment of depression with the Roshi: Journal of Neurotherapy Vol 4(2) 2000, 45-56.
  • Hansen, P. E. B. (2001). "Intractable depression or psychosis": Comment: Acta Psychiatrica Scandinavica Vol 104(5) Nov 2001, 405.
  • Hawley, C., Sivakumaran, T., Huber, T. J., & Ige, A. K. (1998). Combination therapy with nefazodone and lithium: Safety and tolerability in fourteen patients: International Journal of Psychiatry in Clinical Practice Vol 2(4) Dec 1998, 251-254.
  • Hawley, C. J., Ratnam, S., Pattinson, H. A., Quick, S. J., & Echlin, D. (1996). Safety and tolerability of combined treatment with moclobemide and SSRIs: A preliminary study of 19 patients: Journal of Psychopharmacology Vol 10(3) 1996, 241-245.
  • Hawley, C. J., Roberts, A. G., & Walker, M. H. (1994). Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions: Journal of Psychopharmacology Vol 8(4) 1994, 266-267.
  • Heath, S. (2007). Reactive depression and remission rates in the STAR*D trials: American Journal of Psychiatry Vol 164(4) Apr 2007, 680-681.
  • Heindl, A. (2001). How frequent are chronic resp. So-called therapy resistent depressions? Results of a study at specialized depression units: Krankenhauspsychiatrie Vol 12(Suppl1) Sep 2001, S28-S33.
  • Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., et al. (2006). Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder: Journal of Affective Disorders Vol 93(1-3) Jul 2006, 239-243.
  • Hickie, I., Bennett, B., Mitchell, P., Wilhelm, K., & et al. (1996). Clinical and subclinical hypothyroidism in patients with chronic and treatment-resistant depression: Australian and New Zealand Journal of Psychiatry Vol 30(2) Apr 1996, 246-252.
  • Higuchi, H., Kamata, M., Sugawara, Y., & Yoshida, K. (2005). Remarkable Effect of Selegiline (L-Deprenyl), a Selective Monoamine Oxidase Type-B Inhibitor, in a Patient With Severe Refractory Depression: A Case Report: Clinical Neuropharmacology Vol 28(4) Jul-Aug 2005, 191-192.
  • Hihn, H., Baune, B. T., Michael, N., Markowitsch, H., Arolt, V., & Pfleiderer, B. (2006). Memory Performance in Severely Depressed Patients Treated by Electroconvulsive Therapy: Journal of ECT Vol 22(3) Sep 2006, 189-195.
  • Hinrichsen, G. A. (1995). Treatment resistant depression in the elderly: International Journal of Geriatric Psychiatry Vol 10(11) Nov 1995, 991-992.
  • Hirschfeld, R. M. A. (2002). The use of mirtazapine in difficult-to-treat patient populations: Human Psychopharmacology: Clinical and Experimental Vol 17(Suppl1) Jun 2002, S33-S36.
  • Hirschfeld, R. M. A., Montgomery, S. A., Aguglia, E., Amore, M., Delgado, P. L., Gastpar, M., et al. (2002). Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options: Journal of Clinical Psychiatry Vol 63(9) Sep 2002, 826-837.
  • Hodgkiss, A. D. (1995). Lithium augmentation: British Journal of Psychiatry Vol 166(5) May 1995, 679.
  • Hodgkiss, A. D., & Bridges, P. K. (1994). Case report 3: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 367-368.
  • Hoencamp, E., Haffmans, P. M. J., Dijken, W. A., Hoogduin, C. A. L., & et al. (1994). Brofaromine versus lithium addition to maportiline: A double-blind study in maprotiline refractory depressed outpatients: Journal of Affective Disorders Vol 30(3) Mar 1994, 219-227.
  • Hoflich, G., Kasper, S., Hufnagel, A., Ruhrmann, S., & et al. (1993). Application of transcranial magnetic stimulation in treatment of drug-resistant major depression: A report of two cases: Human Psychopharmacology: Clinical and Experimental Vol 8(5) Sep-Oct 1993, 361-365.
  • Hollander, E., & Wong, C. M. (2000). Spectrum, boundary, and subtyping issues: Implications for treatment-refractory obsessive-compulsive disorder. Mahwah, NJ: Lawrence Erlbaum Associates Publishers.
  • Holroyd, S., & Durgee, J. (1998). Venlafaxine in treatment refractory geriatric depression: Clinical Gerontologist Vol 18(3) 1998, 39-50.
  • Holtzheimer, P. E., III, & Avery, D. H. (2005). Focal Brain Stimulation For Treatment-Resistant Depression: Transcranial Magnetic Stimulation, Vagus-Nerve Stimulation, and Deep-Brain Stimulation: Primary Psychiatry Vol 12(2) Feb 2005, 57-64.
  • Hornig, M., Mozley, P. D., & Amsterdam, J. D. (1997). HMPAO spect brain imaging in treatment-resistant depression: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 21(7) Oct 1997, 1097-1114.
  • Hornig-Rohan, M., & Amsterdam, J. D. (1994). Clinical and biological correlates of treatment-resistant depression: An overview: Psychiatric Annals Vol 24(5) May 1994, 220-227.
  • Hornig-Rohan, M., Wolkowitz, O. M., & Amsterdam, J. D. (1996). Novel strategies for treatment-resistant depression: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 387-405.
  • Howland, R. H. (2006). Vagus Nerve Stimulation for Depression and Other Neuropsychiatric Disorders: Journal of Psychosocial Nursing & Mental Health Services Vol 44(9) Sep 2006, 11-14.
  • Huang, C.-C., Su, T.-P., & Shan, I.-K. (2004). A case report of repetitive transcranial magnetic stimulation-induced mania: Bipolar Disorders Vol 6(5) Oct 2004, 444-445.
  • Huang, C.-C., Su, T.-P., Shan, I.-K., Chang, K., & Wei, I. H. (2004). An open trial of daily left prefrontal cortex repetitive transcranial magnetic stimulation for treating medication-resistant depression: European Psychiatry Vol 19(8) Dec 2004, 523-524.
  • Husain, S. S., Kevan, I. M., Linnell, R., & Scott, A. I. F. (2004). Electroconvulsive therapy in depressive illness that has not responded to drug treatment: Journal of Affective Disorders Vol 83(2-3) Dec 2004, 121-126.
  • Ilivicky, H., Caroff, S. N., & Simone, A. F. (1995). Etomidate during ECT for elderly seizure-resistant patients: American Journal of Psychiatry Vol 152(6) Jun 1995, 957-958.
  • Inoue, T., Tsuchiya, K., Miura, J., Sakakibara, S., & et al. (1996). Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression: Biological Psychiatry Vol 40(2) Jul 1996, 151-153.
  • Iosifescu, D. V., Nierenberg, A. A., Mischoulon, D., Perlis, R. H., Papakostas, G. I., Ryan, J. L., et al. (2005). An Open Study of Triiodothyronine Augmentation of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Major Depressive Disorder: Journal of Clinical Psychiatry Vol 66(8) Aug 2005, 1038-1042.
  • Isenberg, K., Downs, D., Pierce, K., Svarakic, D., Garcia, K., Jarvis, M., et al. (2005). Low Frequency rTMS Stimulation of the Right Frontal Cortex Is as Effective as High Frequency rTMS Stimulation of the Left Frontal Cortex for Antidepressant-Free, Treatment-Resistant Depressed Patients: Annals of Clinical Psychiatry Vol 17(3) Jul-Sep 2005, 153-159.
  • IsHak, W. W., Rapaport, M. H., & Gotto, J. G. (2004). Emerging Treatment Options in Treatment-Resistant Depression and Anxiety Disorders: CNS Spectrums Vol 9(12,Suppl14) Dec 2004, 25-32.
  • James, A. (1999). Resistant depression in childhood and adolescence: Clinical Child Psychology and Psychiatry Vol 4(4) Oct 1999, 483-491.
  • Janssen, J., Pol, H. E. H., Schnack, H. G., Kok, R. M., Lampe, I. K., de Leeuw, F.-E., et al. (2007). Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression: International Journal of Geriatric Psychiatry Vol 22(5) May 2007, 468-474.
  • Jerrett, J. G., & Steffens, D. C. (1995). Carbon monoxide-related organic mood disorder successfully treated with ECT: Journal of Clinical Psychiatry Vol 56(7) Jul 1995, 332-333.
  • Joffe, H., Groninger, H., Soares, C., Nonacs, R., & Cohen, L. S. (2001). An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy: Journal of Women's Health & Gender-Based Medicine Vol 10(10) Dec 2001, 999-1004.
  • Joffe, R. T. (1997). Refractory depression: Treatment strategies, with particular reference to the thyroid axis: Journal of Psychiatry & Neuroscience Vol 22(5) Nov 1997, 327-331.
  • Joffe, R. T. (1998). The use of thyroid supplements to augment antidepressant medication: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 26-31.
  • Joffe, R. T. (1999). Peripheral thyroid hormone levels in treatment resistant depression: Biological Psychiatry Vol 45(8) Apr 1999, 1053-1055.
  • Joffe, R. T. (1999). Substitution therapy in patients with major depression: CNS Drugs Vol 11(3) Mar 1999, 175-180.
  • Joffe, R. T. (2000). Substitution therapy in patients with major depression. Kwai Chung, Hong Kong: Adis International Publications.
  • Joffe, R. T. (2002). Should thyroid replacement therapy be considered for patients with treatment-refractory depression? : Journal of Psychiatry & Neuroscience Vol 27(1) Jan 2002, 80.
  • Joffe, R. T., & Levitt, A. J. (1995). Antidepressant failure: Augmentation or substitution? : Journal of Psychiatry & Neuroscience Vol 20(1) Jan 1995, 7-9.
  • Joffe, R. T., & Schuller, D. R. (1993). An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression: Journal of Clinical Psychiatry Vol 54(7) Jul 1993, 269-271.
  • Jorge, R. E., Robinson, R. G., Tateno, A., Narushima, K., Acion, L., Moser, D., et al. (2004). Repetitive Transcranial Magnetic Stimulation as Treatment of Poststroke Depression: A Preliminary Study: Biological Psychiatry Vol 55(4) Feb 2004, 398-405.
  • Kalayam, B., & Alexopoulos, G. S. (1999). Prefrontal dysfunction and treatment response in geriatric depression: Archives of General Psychiatry Vol 56(8) Aug 1999, 713-718.
  • Kamholz, B. A., & Mellow, A. M. (1996). Management of treatment resistance in the depressed geriatric patient: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 269-286.
  • Kaplan, E. M. (2002). Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study: Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy Vol 24(7) Jul 2002, 1194-1200.
  • Kaplan, M. J., & Klinetob, N. A. (2000). Childhood emotional trauma and chronic posttraumatic stress disorder in adult outpatients with treatment-resistant depression: Journal of Nervous and Mental Disease Vol 188(9) Sep 2000, 596-601.
  • Kaschka, W. P., & Jandl, M. (2005). Treatment-resistant depression: An update: Nervenheilkunde: Zeitschrift fur interdisziplinaere Fortbildung Vol 24(4) 2005, 317-321.
  • Katona, C. L. E. (1995). Refractory depression: A review with particular reference to the use of lithium augmentation: European Neuropsychopharmacology Vol 5(Suppl) 1995, 109-113.
  • Katona, C. L. E., Abou-Saleh, M. T., Harrison, D. A., Nairac, B. A., & et al. (1995). Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine: British Journal of Psychiatry Vol 166 Jan 1995, 80-86.
  • Katona, C. L. E., & Robertson, M. M. (1997). Lithium augmentation in refractory depression. Hoboken, NJ: John Wiley & Sons Inc.
  • Kats, S., Bruijn, J. A., Blondeau, M. J. C. E., & van den Broek, W. W. (2003). ECT as compulsory treatment. A case study: Tijdschrift voor Psychiatrie Vol 45(1) 2003, 45-49.
  • Kauffmann, C. D., Cheema, M. A., & Miller, B. E. (2004). Slow Right Prefrontal Transcranial Magnetic Stimulation as a Treatment for Medication-Resistant Depression: A Double-Blind, Placebo-Controlled Study: Depression and Anxiety Vol 19(1) 2004, 59-62.
  • Kemp, D. E., Gilmer, W. S., Fleck, J., Straus, J. L., Dago, P. L., & Karaffa, M. (2007). Aripiprazole augmentation in treatment-resistant bipolar depression: Early response and development of akathisia: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 31(2) Mar 2007, 574-577.
  • Kennedy, N., & McDonough, M. (2003). Pharmacological management of treatment resistant depression: A clinical review: Irish Journal of Psychological Medicine Vol 20(1) Mar 2003, 18-23.
  • Kennedy, N., & Paykel, E. S. (2004). Treatment and response in refractory depression: results from a specialist affective disorders service: Journal of Affective Disorders Vol 81(1) 2004, 49-53.
  • Kennedy, S. H., & Giacobbe, P. (2007). Treatment resistant depression--Advances in somatic therapies: Annals of Clinical Psychiatry Vol 19(4) Oct 2007, 279-287.
  • Kennedy, S. H., & Lam, R. W. (2003). Enhancing outcomes in the management of treatment resistant depression: A focus on atypical antipsychotics: Bipolar Disorders Vol 5(Suppl2) Dec 2003, 36-47.
  • Kennedy, S. H., Segal, Z. V., Cohen, N. L., Levitan, R. D., Gemar, M., & Bagby, R. M. (2003). Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: An exploratory trial: Journal of Clinical Psychiatry Vol 64(4) Apr 2003, 439-444.
  • Kenny, M. A., & Williams, J. M. G. (2007). Treatment-resistant depressed patients show a good response to Mindfulness-based Cognitive Therapy: Behaviour Research and Therapy Vol 45(3) Mar 2007, 617-625.
  • Ketter, T. A., Wang, P. W., Chandler, R. A., Culver, J. L., & Alarcon, A. M. (2006). Adjunctive Aripiprazole in Treatment-Resistant Bipolar Depression: Annals of Clinical Psychiatry Vol 18(3) Jul-Sep 2006, 169-172.
  • Khalid, N., Atkins, M., & Kirov, G. (2006). The Effects of Etomidate on Seizure Duration and Electrical Stimulus Dose in Seizure-resistant Patients During Electroconvulsive Therapy: Journal of ECT Vol 22(3) Sep 2006, 184-188.
  • Kindler, S., Sasson, Y., Cohen, R., & Zohar, J. (1994). The role of oestrogen augmentation in females with refractory depression. Oxford, England: John Wiley & Sons.
  • Kindler, S., Sasson, Y., Dolberg, O., & Zohar, J. (1994). The role of reserpine augmentation in refractory depression. Oxford, England: John Wiley & Sons.
  • Kishida, I., Aklillu, E., Kawanishi, C., Bertilsson, L., & Agren, H. (2007). Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression: Neuropsychopharmacology Vol 32(10) Oct 2007, 2143-2151.
  • Klein, N., Sacher, J., Wallner, H., Tauscher, J., & Kasper, S. (2004). Therapy of Treatment Resistant Depression: Focus on the Management of TRD with Atypical Antipsychotics: CNS Spectrums Vol 9(11,Suppl12) Nov 2004, 823-832.
  • Klein, P., & Oertel, J. (1997). Depression associated with pontine vascular malformation: Biological Psychiatry Vol 42(6) Sep 1997, 519-521.
  • Knoll, J., Stegman, K., & Suppes, T. (1998). Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania: Journal of Affective Disorders Vol 49(3) Jun 1998, 229-233.
  • Kohler, C. G., & Burock, M. (2001). ECT for psychotic depression associated with a brain tumor: American Journal of Psychiatry Vol 158(12) Dec 2001, 2089.
  • Kok, R. M., & van Maarschalkerweerd, W. W. A. (2004). Treatment resistant depression in the elderly: When is it inadvisable to prescribe tricyclic antidepressants? : Tijdschrift voor Psychiatrie Vol 46(11) 2004, 769-773.
  • Kok, R. M., Vink, D., Heeren, T. J., & Nolen, W. A. (2007). Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: An open, randomized, controlled trial: Journal of Clinical Psychiatry Vol 68(8) Aug 2007, 1177-1185.
  • Konig, F., & Wolfersdorf, M. (1997). Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression: Pharmacopsychiatry Vol 30(3) May 1997, 93-96.
  • Konig, F., Wolfersdorf, M., Loble, M., Wossner, S., & Hauger, B. (1997). Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression: Pharmacopsychiatry Vol 30(4) Jul 1997, 125-127.
  • Kornstein, S. G., & Schneider, R. K. (2001). Clinical features of treatment-resistant depression: Journal of Clinical Psychiatry Vol 62(Suppl16) 2001, 18-25.
  • Kosel, M., Frick, C., Lisanby, S. H., Fisch, H.-U., & Schlaepfer, T. E. (2003). Magnetic seizure therapy improves mood in refractory major depression: Neuropsychopharmacology Vol 28(11) Nov 2003, 2045-2048.
  • Kosel, M., & Schlaepfer, T. E. (2002). Mechanisms and state of the art of vagus nerve stimulation: Journal of ECT Vol 18(4) Dec 2002, 189-192.
  • Kosel, M., Sturm, V., Frick, C., Lenartz, D., Zeidler, G., Brodesser, D., et al. (2007). Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression: Journal of Psychiatric Research Vol 41(9) Nov 2007, 801-803.
  • Kotler, M., & Matar, M. A. (1998). Lamotrigine in the treatment of resistant bipolar disorder: Clinical Neuropharmacology Vol 21(1) Feb 1998, 65-67.
  • Kozel, F. A., & George, M. S. (2005). Neuroimaging and Depression with Inadequate Treatment Response: Primary Psychiatry Vol 12(2) Feb 2005, 30-35.
  • Krahn, L. E., Gleber, E., Rummans, T. A., Pileggi, T. S., Lucas, D. L., & Li, H. (2000). The effects of electroconvulsive therapy on melatonin: Journal of ECT Vol 16(4) Dec 2000, 391-398.
  • Kratochvil, C. J., Wagner, K. D., Emslie, G., & March, J. (2005). Pharmacological Management of Treatment-Resistant Pediatric Depression: Journal of the American Academy of Child & Adolescent Psychiatry Vol 44(2) Feb 2005, 198-200.
  • Kubera, M., Lin, A.-H., Kenis, G., Bosmans, E., Bockstaele, D. v., & Maes, M. (2001). Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma /interleukin-10 production ratio: Journal of Clinical Psychopharmacology Vol 21(2) Apr 2001, 199-206.
  • Kumari, V., Mitterschiffthaler, M. T., Teasdale, J. D., Malhi, G. S., Brown, R. G., Giampietro, V., et al. (2003). Neural Abnormalities during Cognitive Generation of Affect in Treatment-Resistant Depression: Biological Psychiatry Vol 54(8) Oct 2003, 777-791.
  • Kunik, M. E., Pollock, B. G., Perel, J. M., & Altieri, L. (1994). Clomipramine in the elderly: Tolerance and plasma levels: Journal of Geriatric Psychiatry and Neurology Vol 7(3) Jul-Sep 1994, 139-143.
  • Kusumakar, V., & Yatham, L. N. (1997). An open study of lamotrigine in refractory bipolar depression: Psychiatry Research Vol 72(2) Sep 1997, 145-148.
  • Labbate, L. A., & Rubey, R. N. (1997). Lamotrigine for treatment-refractory bipolar disorder: American Journal of Psychiatry Vol 154(9) Sep 1997, 1317.
  • Labiner, D. M., & Ahern, G. L. (2007). Vagus nerve stimulation therapy in depression and epilepsy: Therapeutic parameter settings: Acta Neurologica Scandinavica Vol 115(1) Jan 2007, 23-33.
  • Lam, R. W., Bartley, S., Yatham, L. N., Tam, E. M., & Zis, A. P. (1999). Clinical predictors of short-term outcome in electroconvulsive therapy: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 44(2) Mar 1999, 158-163.
  • Lam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004). Citalopram and Bupropion-SR: Combining Versus Switching in Patients With Treatment-Resistant Depression: Journal of Clinical Psychiatry Vol 65(3) Mar 2004, 337-340.
  • Lam, R. W., Wan, D. D. C., Cohen, N. L., & Kennedy, S. H. (2002). Combining antidepressants for treatment-resistant depression: A review: Journal of Clinical Psychiatry Vol 63(8) Aug 2002, 685-693.
  • Landen, M., Bjorling, G., Agren, H., & Fahlen, T. (1998). A randomized, double-blind, placebo-controlled trial of busiprone in combination with an SSRI in patients with treatment-refractory depression: Journal of Clinical Psychiatry Vol 59(12) Dec 1998, 664-668.
  • Lane, H.-Y., & Chang, W.-H. (1998). Risperidone monotherapy for psychotic depression unresponsive to other treatments: Journal of Clinical Psychiatry Vol 59(11) Nov 1998, 624.
  • Lang, U. E., Bajbouj, M., Gallinat, J., & Hellweg, R. (2006). Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation: Psychopharmacology Vol 187(1) Jul 2006, 56-59.
  • Langer, G., Karazman, R., Neumark, J., Saletu, B., & et al. (1995). Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment: A double-blind comparison with electroconvulsive treatment: Neuropsychobiology Vol 31(4) 1995, 182-194.
  • Lapid, M. I., Rummans, T. A., Hofmann, V. E., & Olney, B. A. (2001). ECT and automatic internal cardioverter-defibrillator: Journal of ECT Vol 17(2) Jun 2001, 146-148.
  • Lattanzi, L., Dell'Osso, L., Cassano, P., Pini, S., Rucci, P., Houck, P. R., et al. (2002). Pramipexole in treatment-resistant depression: A 16-week naturalistic study: Bipolar Disorders Vol 4(5) Oct 2002, 307-314.
  • Laugharne, J., & Peet, M. (1996). Treatment-resistant depression in the elderly: International Journal of Geriatric Psychiatry Vol 11(1) Jan 1996, 84.
  • Lee, W., & Cleare, A. (2003). Lithium augmentation in treatment-refractory unipolar depression: British Journal of Psychiatry Vol 182(5) May 2003, 456.
  • Levine, J., Gonsalves, M., Babur, I., Stier, S., & et al. (1993). Inositol 6 g daily may be effective in depression but not in schizophrenia: Human Psychopharmacology: Clinical and Experimental Vol 8(1) Jan-Feb 1993, 49-53.
  • Levy, E., & Margolese, H. C. (2003). Migraine headache prophylaxis and treatment with low-dose mirtazapine: International Clinical Psychopharmacology Vol 18(5) Sep 2003, 301-303.
  • Lewis, G., Stimpson, N., & Agrawal, N. (2003). "Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review": Reply: British Journal of Psychiatry Vol 182(5) May 2003, 456-457.
  • Lojko, D., & Rybakowski, J. K. (2007). L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression: Journal of Affective Disorders Vol 103(1-3) Nov 2007, 253-256.
  • Loo, C., Mitchell, P., Sachdev, P., McDarmont, B., Parker, G., & Gandevia, S. (1999). Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression: American Journal of Psychiatry Vol 156(6) Jun 1999, 946-948.
  • Loo, C. K., Mitchell, P. B., Croker, V. M., Malhi, G. S., Wen, W., Gandevia, S. C., et al. (2003). Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimiulation for the treatment of resistant major depression: Psychological Medicine Vol 33(1) Jan 2003, 33-40.
  • Lopez-Munoz, F., Alamo, C., Rubio, G., Garcia-Garcia, P., & Pardo, A. (2007). Reboxetine combination in treatment-resistant depression to Selective Serotonin Reuptake Inhibitors: Pharmacopsychiatry Vol 40(1) Jan 2007, 14-19.
  • Lopez-Munoz, F., Rubio, G., Alamo, C., Garcia-Garcia, P., & Pardo, A. (2006). Reboxetine Addition in Patients With Mirtazapine-resistant Depression: A Case Series: Clinical Neuropharmacology Vol 29(4) Jul-Aug 2006, 192-196.
  • Loze, J. Y., Azorin, J. M., Leguay, D., Parquet, P., Sechter, D., & Rouillon, F. (2001). Pharmaco-epidemiological survey about introduction and continuation of antidepressant treatments (EPICTA): Annales Medico-Psychologiques Vol 159(8) Oct 2001, 600-604.
  • Luborzewski, A., Regen, F., Schindler, F., & Anghelescu, I. (2006). Modafinil-Induced Reversible Hyperkinetic Nondystonic Movement Disorder in a Patient With Major Depressive Disorder: Journal of Neuropsychiatry & Clinical Neurosciences Vol 18(2) Spr 2006, 248-249.
  • Lurie, P., & Stine, N. (2006). Responding to Three Articles Regarding Vagus Nerve Stimulation (VNS) for Depression: Biological Psychiatry Vol 60(12) Dec 2006, 1382.
  • Macaskill, N. D. (1994). Case report 4: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 368-369.
  • Maes, M., De Meester, I., Verkerk, R., De Medts, P., Wauters, A., Vanhoof, G., et al. (1997). Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: Relationships with immune-inflammatory markers: Psychoneuroendocrinology Vol 22(2) Feb 1997, 65-78.
  • Maes, M., Vandoolaeghe, E., & Desnyder, R. (1996). Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression: Journal of Affective Disorders Vol 41(3) Dec 1996, 201-210.
  • Maes, M., Vandoolaeghe, E., Neels, H., Demedts, P., & et al. (1997). Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness: Biological Psychiatry Vol 42(5) Sep 1997, 349-358.
  • Maes, M., Vandoolaeghe, E., van Hunsel, F., & Bril, T. (1997). Immune disturbances in treatment-resistant depression: Modulation by antidepressive treatments: Human Psychopharmacology: Clinical and Experimental Vol 12(2) Mar-Apr 1997, 153-162.
  • Maes, M., Verkerk, R., Vandoolaeghe, E., Hunsel, F. V., & et al. (1997). Serotonin-immune interactions in major depression: Lower serum tryptophan as a marker of an immune-inflammatory response: European Archives of Psychiatry and Clinical Neuroscience Vol 247(3) 1997, 154-161.
  • Magder, D. M., Aleksic, I., & Kennedy, S. H. (2000). Tolerability and efficacy of high-dose moclobemide alone and in combination with lithium and trazodone: Journal of Clinical Psychopharmacology Vol 20(3) Jun 2000, 394-395.
  • Mago, R., & Monti, D. (2007). Antiadrenergic treatment of antidepressant-induced excessive sweating in 3 patients: Journal of Clinical Psychiatry Vol 68(4) Apr 2007, 639-640.
  • Maina, G., Portaleone, F., Picco, C., & Bogetto, F. (2003). Definition and therapeutic strategies of treatment resistant depression: A review: Rivista di Psichiatria Vol 38(5) Sep-Oct 2003, 225-240.
  • Maj, M., Pirozzi, R., & Magliano, L. (1995). Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: Prevalence and predictors: American Journal of Psychiatry Vol 152(12) Dec 1995, 1810-1811.
  • Malhi, G. S., & Bridges, P. K. (1997). Management of resistant depression: International Journal of Psychiatry in Clinical Practice Vol 1(4) Dec 1997, 269-276.
  • Malhi, G. S., & Checkley, S. A. (1999). Olanzapine in the treatment of psychotic depression: British Journal of Psychiatry Vol 174 May 1999, 460.
  • Malhi, G. S., & Farmer, A. E. (1999). Drug therapy in treatment-resistant depression: British Journal of Psychiatry Vol 175 Oct 1999, 390-391.
  • Malhi, G. S., Parker, G. B., Crawford, J., Wilhelm, K., & Mitchell, P. B. (2005). Treatment-resistant depression: Resistant to definition? : Acta Psychiatrica Scandinavica Vol 112(4) Oct 2005, 302-309.
  • Malison, R. T., Anand, A., Pelton, G. H., Kirwin, P., Carpenter, L., McDougle, C. J., et al. (1999). Limited efficacy of ketoconazole in treatment-refractory major depression: Journal of Clinical Psychopharmacology Vol 19(5) Oct 1999, 466-470.
  • Malizia, A. L., Allen, S. J., Maisey, M. N., Bartlett, J. R., & Bridges, P. K. (1994). Changes in low frontal cerebral blood flow correlate with outcome in stereotactic subcaudate tractotomy carried out for refractory depression. Oxford, England: John Wiley & Sons.
  • Maltese, T. M. (1999). Adjunctive lamotrigine treatment for major depression: American Journal of Psychiatry Vol 156(11) Nov 1999, 1833.
  • Maltsberger, J. T., Ackerman, S., & Wheelis, J. (2002). Simon Muralis: Self-sequestration and psychotherapeutic failure: Suicide and Life-Threatening Behavior Vol 32(4) 2002, 441-450.
  • Maluquer, S. S., Arranz, B., & San, L. (2002). Depression improvement with calcium heparin: General Hospital Psychiatry Vol 24(6) Nov-Dec 2002, 450-451.
  • Manning, J. S. (2003). Difficult-to-treat depressions: A primary care perspective: Journal of Clinical Psychiatry Vol 64(Suupl1) 2003, 24-31.
  • Manning, J. S., Haykal, R. F., Connor, P. D., Cunningham, P. D., Jackson, W. C., & Long, S. (2005). Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament: Journal of Affective Disorders Vol 84(2-3) Feb 2005, 259-266.
  • Marangell, L. B. (2000). Augmentation of standard depression therapy: Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy Vol (22,SupplA) 2000, A25-A38.
  • Marangell, L. B. (2001). Switching antidepressants for treatment-resistant major depression: Journal of Clinical Psychiatry Vol 62(Suppl18) 2001, 12-17.
  • Marangell, L. B., George, M. S., Callahan, A. M., Ketter, T. A., & et al. (1997). Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients: Archives of General Psychiatry Vol 54(3) Mar 1997, 214-222.
  • Marangell, L. B., Martinez, M., Jurdi, R. A., & Zboyan, H. (2007). Neurostimulation therapies in depression: A review of new modalities: Acta Psychiatrica Scandinavica Vol 116(3) Sep 2007, 174-181.
  • Marangell, L. B., Rush, A. J., George, M. S., Sackeim, H. A., Johnson, C. R., Husain, M. M., et al. (2002). Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes: Biological Psychiatry Vol 51(4) Feb 2002, 280-287.
  • Marangell, L. B., Rush, J. A., George, M. S., Georges, D., & Sackeim, H. A. (2001). A review of vagus nerve stimulation for treatment-resistant depression: Epilepsy & Behavior Vol 2(3,Part2) Jun 2001, S6-S10.
  • Markwort, S., Cordes, P., & Aldenhoff, J. (1997). Transcranial magnet stimulation as a therapeutic alternative to electroconvulsive therapy in therapy-resistant depressions: Fortschritte der Neurologie, Psychiatrie Vol 65(12) Dec 1997, 540-549.
  • Marshall, R. D., & Liebowitz, M. R. (1996). Paroxetine/bupropion combination treatment for refractory depression: Journal of Clinical Psychopharmacology Vol 16(1) Feb 1996, 80-81.
  • Martin, L., Bakish, D., & Joffe, R. (1994). MAOI treatment of depression. Washington, DC: American Psychiatric Association.
  • Masaquel, A., Wells, K., & Ettner, S. L. (2007). How does the persistence of depression influence the continuity and type of health insurance and coverage limits on mental health therapy? : Journal of Mental Health Policy and Economics Vol 10(3) Sep 2007, 133-144.
  • Masdrakis, V. G., Kontaxakis, V. P., & Christodoulou, G. N. (2001). Therapeutic strategies in treatment-resistant depression: Psychiatriki Vol 12(1) Jan-Mar 2001, 25-41.
  • Maskall, D. D., & Lam, R. W. (1993). Increased plasma concentration of imipramine following augmentation with fluvoxamine: American Journal of Psychiatry Vol 150(10) Oct 1993, 1566.
  • Mathew, S. J., Amiel, J. M., & Sackeim, H. A. (2005). Electroconvulsive Therapy in Treatment-Resistant Depression: Primary Psychiatry Vol 12(2) Feb 2005, 52-56.
  • Maybaum, L., & Crockford, D. (1999). Electroconvulsive therapy, personality structure, and suicide: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 44(9) Nov 1999, 922-923.
  • Maytal, G., Ostacher, M., & Stern, T. A. (2006). Aripiprazole-Related Tardive Dyskinesia: CNS Spectrums Vol 11(6) Jun 2006, 435-439.
  • Mazeh, D., Melamed, Y., & Elizur, A. (1999). Venlafaxine in the treatment of resistant postpsychotic depressive symptoms of schizophrenia: Journal of Clinical Psychopharmacology Vol 19(3) Jun 1999, 284-285.
  • Mbaya, P. (2002). Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression: Human Psychopharmacology: Clinical and Experimental Vol 17(7) Oct 2002, 335-339.
  • McDonald, W. M., Easley, K., Byrd, E. H., Holtzheimer, P., Tuohy, S., Woodard, J. L., et al. (2006). Combination rapid transcranial magnetic stimulation in treatment refractory depression: Neuropsychiatric Disease And Treatment Vol 2(1) Jan 2006, 85-94.
  • McDonald, W. M., Phillips, V. L., Figiel, G. S., Marsteller, F. A., Simpson, C. D., & Bailey, M. C. (1998). Cost-effective maintenance treatment of resistant geriatric depression: Psychiatric Annals Vol 28(1) Jan 1998, 47-52.
  • McElroy, S. L., Frye, M., Denicoff, K., Altshuler, L., Nolen, W., Kupka, R., et al. (1998). Olanzapine in treatment-resistant bipolar disorder: Journal of Affective Disorders Vol 49(2) May 1998, 119-122.
  • McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report: American Journal of Psychiatry Vol 163(9) Sep 2006, 1531-1541.
  • McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., et al. (2007). "Star*D Study Team: Tranylcypromine versus venalafaxine plus mirtazepine following three failed antidepressant medication trials for depression: A STAR*D report": Reply: American Journal of Psychiatry Vol 164(3) Mar 2007, 524.
  • McLeod, M. N., Gaynes, B. N., & Golden, R. N. (1999). Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients: Journal of Clinical Psychiatry Vol 60(4) Apr 1999, 237-240.
  • McPherson, S., Cairns, P., Carlyle, J., Shapiro, D. A., Richardson, P., & Taylor, D. (2005). The effectiveness of psychological treatments for treatment-resistant depression: A systematic review: Acta Psychiatrica Scandinavica Vol 111(5) May 2005, 331-340.
  • McPherson, S., Walker, C., & Caryle, J.-A. (2006). Primary care counsellors' experiences of working with treatment resistant depression: A qualitative pilot study: Counselling & Psychotherapy Research Vol 6(4) Dec 2006, 250-257.
  • Meltzer, H. Y., Maes, M., & Elkis, H. (1994). The biological basis of refractory depression. Oxford, England: John Wiley & Sons.
  • Menza, M. (2006). STAR*D: The Results Begin to Roll in: American Journal of Psychiatry Vol 163(7) Jul 2006, 1123-1125.
  • Mervaala, E., Fohr, J., Kononen, M., Valkonen-Korhonen, M., Vainio, P., Partanen, K., et al. (2000). Quantitative MRI of the hippocampus and amygdala in severe depression: Psychological Medicine Vol 30(1) Jan 2000, 117-125.
  • Mervaala, E., Kononen, M., Fohr, J., Husso-Saastamoinen, M., Valkonen-Korhonen, M., Kuikka, J. T., et al. (2001). SPECT and neuropsychological performance in severe depression treated with ECT: Journal of Affective Disorders Vol 66(1) Sep 2001, 47-58.
  • Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., & Pfleiderer, B. (2003). Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression: Psychological Medicine Vol 33(7) Oct 2003, 1277-1284.
  • Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., & Pfleiderer, B. (2003). Neurotrophic effects of electroconvulsive therapy: A proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression: Neuropsychopharmacology Vol 28(4) Apr 2003, 720-725.
  • Michalak, E. E., & Lam, R. W. (2002). Breaking the myths: New treatment approaches for chronic depression: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 47(7) Sep 2002, 635-643.
  • Miller, H. L., Ekstrom, R. D., Mason, G. A., Lydiard, R. B., & Golden, R. N. (2001). Noradrenergic function and clinical outcome in antidepressant pharmacotherapy: Neuropsychopharmacology Vol 24(6) Jun 2001, 617-623.
  • Mirabel-Sarron, C., Morell, C., & Samuel-Lajeunesse, B. (1993). Beck's cognitive therapy for patients with pharmacotherapy-resistant chronic depression: Annales Medico-Psychologiques Vol 151(10) Dec 1993, 697-701.
  • Mirsal, H., Kalyoncu, A., Pektas, O., Tan, D., & Beyazyurek, M. (2003). Olanzapine augmentation in elderly patients with treatment-resistant major depression: an open trial: Klinik Psikofarmakoloji Bulteni Vol 13(1) 2003, 1-5.
  • Mischoulon, D., Nierenberg, A. A., Kizilbash, L., Rosenbaum, J. F., & Fava, M. (2000). Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 45(5) Jun 2000, 476-481.
  • Mitchell, P. B., Schweitzer, I., Burrows, G., Johnson, G., & Polonowita, A. (2000). Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression: Journal of Clinical Psychopharmacology Vol 20(4) Aug 2000, 483-487.
  • Miura, J., Tsuchiya, K., Inoue, T., Sakakibara, S., Denda, K., Kasahara, T., et al. (1996). Effect of bromocriptine for treatment-resistant depression: Seishin Igaku (Clinical Psychiatry) Vol 38(4) Apr 1996, 399-404.
  • Moller, H. J. (1991). Non-response to antidepressants: Risk factors and therapeutic possibilities: Nervenarzt Vol 62(11) Nov 1991, 658-669.
  • Moller, H. J. (1994). Drug therapy and other biological approaches in the treatment of resistant depression: Possibilities and limitations. Ashland, OH: Hogrefe & Huber Publishers.
  • Moller, H. J. (1994). Non-response to antidepressants: Risk factors and therapeutic possibilities: International Clinical Psychopharmacology Vol 9(Suppl 2) Jun 1994, 17-23.
  • Moller, H. J. (2004). Resistance to antidepressant therapy. Definition, frequency, predictive factors, and medical strategies: Nervenarzt Vol 75(5) 2004, 499-517.
  • Moore, R. G., & Blackburn, I.-M. (1997). Cognitive therapy in the treatment of non-responders to antidepressant medication: A controlled pilot study: Behavioural and Cognitive Psychotherapy Vol 25(3) 1997, 251-259.
  • Moreno, D. H., Moreno, R. A., & Cali, H. M. (1994). A Brazilian experience of treatment-resistant depression: International Clinical Psychopharmacology Vol 9(Suppl 2) Jun 1994, 11-16.
  • Moreno, D. H., Moreno, R. A., & Calil, H. M. (1993). Treatment-resistant depression: A Brazilian experience: Revista ABP-APAL Vol 15(4) Oct-Dec 1993, 146-148.
  • Moreno, F. A., Gelenberg, A. J., Bachar, K., & Delgado, P. L. (1997). Pindolol augmentation of treatment-resistant depressed patients: Journal of Clinical Psychiatry Vol 58(10) Oct 1997, 437-439.
  • Morgan, P. T. (2007). Treatment-resistant depression: Response to low-dose transdermal but not oral selegiline: Journal of Clinical Psychopharmacology Vol 27(3) Jun 2007, 313-314.
  • Morishita, S., & Aoki, S. (1999). Clonazepam in the treatment of prolonged depression: Journal of Affective Disorders Vol 53(3) Jun 1999, 275-278.
  • Morishita, S., & Arita, S. (2003). Lithium Augmentation of Antidepressants in the Treatment of Protracted Depression: International Medical Journal Vol 10(1) Mar 2003, 29-32.
  • Morishita, S., & Arita, S. (2007). Clonazepam augmentation of antidepressants: Which is the suitable combined antidepressant? : International Medical Journal Vol 14(3) Sep 2007, 195-197.
  • Morishita, S., Sonohara, M., Murakami, H., Matsushita, K., Ebata, J., Koshikawa, T., et al. (2000). Vitamin E treatment of prolonged depression: A report of nine cases: International Medical Journal Vol 7(1) Mar 2000, 33-36.
  • Moscariello, M. M., Orlandi, V., Salviati, M., & Biondi, M. (2005). Adjunctive gabapentin in treatment-resistant unipolar depression: Rivista di Psichiatria Vol 40(3) May-Jun 2005, 164-173.
  • Moser, D. J., Jorge, R. E., Manes, F., Paradiso, S., Benjamin, M. L., & Robinson, R. G. (2002). Improved executive functioning following repetitive transcranial magnetic stimulation: Neurology Vol 58(8) Apr 2002, 1288-1290.
  • Mosimann, U. P., Marre, S. C., Schmitt, W., Hess, C. W., Fisch, H. U., & Schlaepfer, T. E. (2002). Antidepressant effects of repetitive transcranial magnetic stimulation in the elderly: Correlation between effect size and coil-cortex distance: Archives of General Psychiatry Vol 59(6) Jun 2002, 560-561.
  • Mosimann, U. P., Schmitt, W., Greenberg, B. D., Kosel, M., Muri, R. M., Berkhoff, M., et al. (2004). Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients: Psychiatry Research Vol 126(2) Apr 2004, 123-133.
  • Mulsant, B. H., & Pollock, B. G. (1998). Treatment-resistant depression in late life: Journal of Geriatric Psychiatry and Neurology Vol 11(4) Win 1998, 186-193.
  • Murashita, J., Kato, T., Shioiri, T., Inubushi, T., & Kato, N. (2000). Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated superscript 3superscript 1P-MR spectroscopy: Psychological Medicine Vol 30(1) Jan 2000, 107-115.
  • Murck, H., Song, C., Horrobin, D. F., & Uhr, M. (2004). Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression: International Journal of Neuropsychopharmacology Vol 7(3) Sep 2004, 341-349.
  • Murphy, B. E. P., Filipini, D., & Ghadirian, A. M. (1993). Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU 486: Journal of Psychiatry & Neuroscience Vol 18(5) Nov 1993, 209-213.
  • Murphy, B. E. P., Ghadirian, A. M., & Dhar, V. (1998). Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 43(3) Apr 1998, 279-286.
  • Nadeau, S. E., McCoy, K. J. M., Crucian, G. P., Greer, R. A., Rossi, F., Bowers, D., et al. (2002). Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: Evidence of individual variability: Neuropsychiatry, Neuropsychology, & Behavioral Neurology Vol 15(3) Sep 2002, 159-175.
  • Nahas, Z., Marangell, L. B., Husain, M. M., Rush, A. J., Sackeim, H. A., Lisanby, S. H., et al. (2005). Two-Year Outcome of Vagus Nerve Stimulation (VNS) for Treatment of Major Depressive Episodes: Journal of Clinical Psychiatry Vol 66(9) Sep 2005, 1097-1104.
  • Nahas, Z., Teneback, C., Chae, J.-H., Mu, Q., Molnar, C., Kozel, F. A., et al. (2007). Serial vagus nerve stimulation functional MRI in treatment-resistant depression: Neuropsychopharmacology Vol 32(8) Aug 2007, 1649-1660.
  • Neimeyer, R. A. (1993). Constructivist psychotherapy. San Francisco, CA: Jossey-Bass.
  • Nelsen, M. R., & Dunner, D. L. (1993). Treatment resistance in unipolar depression and other disorders: Diagnostic concerns and treatment possibilities: Psychiatric Clinics of North America Vol 16(3) Sep 1993, 541-566.
  • Nelsen, M. R., & Dunner, D. L. (1995). Clinical and differential diagnostic aspects of treatment-resistant depression: Journal of Psychiatric Research Vol 29(1) Jan-Feb 1995, 43-50.
  • Nelson, J. C. (1998). Augmentation strategies with serotonergic-noradrenergic combinations: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 65-69.
  • Nelson, J. C. (1998). Overcoming treatment resistance in depression: Journal of Clinical Psychiatry Vol 59(Suppl 16) 1998, 13-19.
  • Nelson, J. C. (1998). Treatment of antidepressant nonresponders: Augmentation or switch? : Journal of Clinical Psychiatry Vol 59(Suppl 15) 1998, 35-41.
  • Nelson, J. C. (2000). Augmentation strategies in depression 2000: Journal of Clinical Psychiatry Vol 61(Suppl 2) 2000, 13-19.
  • Nelson, J. C. (2003). Managing treatment-resistant major depression: Journal of Clinical Psychiatry Vol 64(Suupl1) 2003, 5-12.
  • Nelson, J. C., Mazure, C. M., & Jatlow, P. I. (1994). Characteristics of desipramine-refractory depression: Journal of Clinical Psychiatry Vol 55(1) Jan 1994, 12-19.
  • Nelson, J. C., & Price, L. H. (1995). Lithium or desipramine augmentation of fluoxetine treatment: American Journal of Psychiatry Vol 152(10) Oct 1995, 1538-1539.
  • Nemeroff, C. B., Mayberg, H. S., Krahl, S. E., McNamara, J., Frazer, A., Henry, T. R., et al. (2006). Corrigendum: VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms: Neuropsychopharmacology Vol 31(10) Oct 2006, 2329.
  • Nemeroff, C. B., Mayberg, H. S., Krahl, S. E., McNamara, J., Frazer, A., Henry, T. R., et al. (2006). VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms: Neuropsychopharmacology Vol 31(7) Jul 2006, 1345-1355.
  • Neu, P., Heuser, I., & Bajbouj, M. (2005). Cerebral Blood Flow during Vagus Nerve Stimulation - a Transcranial Doppler Study: Neuropsychobiology Vol 51(4) Jun 2005, 265-268.
  • Newton, S. S., Girgenti, M. J., Collier, E. F., & Duman, R. S. (2006). Electroconvulsive seizure increases adult hippocampal angiogenesis in rats: European Journal of Neuroscience Vol 24(3) Aug 2006, 819-828.
  • Niederhofer, H. (2003). Therapy Resistant Major Depression: Improvement of Symptomatology After Combining Antidepressants with Tianeptine (Stablon.): Psychiatrische Praxis Vol 30(4) May 2003, 221-222.
  • Nierenberg, A. A. (1994). Treatment-resistant depression in the age of serotonin: Psychiatric Annals Vol 24(5) May 1994, 217-219.
  • Nierenberg, A. A., Dougherty, D., & Rosenbaum, J. F. (1998). Dopaminergic agents and stimulants as antidepressant augmentation strategies: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 60-64.
  • Nierenberg, A. A., Fava, M., Alpert, J., Lagomasino, I., Sonawalla, S., Tedlow, J., et al. (2004). "Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants": Reply: Journal of Clinical Psychopharmacology Vol 24(2) Apr 2004, 241-242.
  • Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., et al. (2006). Comparison of Lithium and T-sub-3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report: American Journal of Psychiatry Vol 163(9) Sep 2006, 1519-1530.
  • Nierenberg, A. A., Feighner, J. P., Rudolph, R., Cole, J. O., & et al. (1994). Venlafaxine for treatment-resistant unipolar depression: Journal of Clinical Psychopharmacology Vol 14(6) Dec 1994, 419-423.
  • Nierenberg, A. A., Katz, J., & Fava, M. (2007). A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression: Psychiatric Clinics of North America Vol 30(1) Mar 2007, 13-29.
  • Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R., Ketter, T. A., Marangell, L. B., Miklowitz, D. J., et al. (2006). Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone: American Journal of Psychiatry Vol 163(2) Feb 2006, 210-216.
  • Nierenberg, A. A., Papakostas, G. I., Petersen, T., Kelly, K. E., Iacoviello, B. M., Worthington, J. J., et al. (2003). Nortriptyline for treatment-resistant depression: Journal of Clinical Psychiatry Vol 64(1) Jan 2003, 35-39.
  • Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., et al. (2003). Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants: Journal of Clinical Psychopharmacology Vol 23(1) Feb 2003, 92-95.
  • Nierenberg, A. A., Sachs, G. S., Stoll, A. L., Rybakowski, J., Matkowski, K., Cole, A. J., et al. (1994). Alternative approaches in refractory bipolar depression. Oxford, England: John Wiley & Sons.
  • No authorship, i. (1996). The effect of sequential antidepressant treatment on geriatric depression: Erratum: Journal of Affective Disorders Vol 41(1) Nov 1996, 77.
  • No authorship, i. (2003). Journal of Clinical Psychiatry: CME posttest: Journal of Clinical Psychiatry Vol 64(Suupl1) 2003, 32-33.
  • No authorship, i. (2004). Feature Interview: David Avery, MD on Transcranial Magnetic Stimulation for depression: Essential Psychopharmacology Vol 5(4) 2004, 307-314.
  • No authorship, i. (2004). Popular Augmentation Strategies: A Brief Review: Essential Psychopharmacology Vol 6(1) 2004, 60-64.
  • No authorship, i. (2005). Adjunctive Aripiprazole Effective for Treatment- Resistant Depression: Primary Psychiatry Vol 12(1) Jan 2005, 19.
  • No authorship, i. (2006). Botox treatment of depression: Primary Psychiatry Vol 13(7) Jul 2006, 26-27.
  • No authorship, i. (2006). Visual hallucinations due to the addition of riluzole to memantine and bupropion: Primary Psychiatry Vol 13(6) Jun 2006, 25-26.
  • No authorship, i. (2006). "What Happened to Lithium? Antidepressant Augmentation in Clinical Settings": Erratum: American Journal of Psychiatry Vol 163(9) Sep 2006, No Pagination Specified.
  • Nobler, M. S., & Sackeim, H. A. (1994). Refractory depression and electroconvulsive therapy. Oxford, England: John Wiley & Sons.
  • Nolen, W. A., Haffmans, P. J., Bouvy, P. F., & Duivenvoorden, H. J. (1993). Monoamine oxidase inhibitors in resistant major depression: A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants: Journal of Affective Disorders Vol 28(3) Jul 1993, 189-197.
  • Nolen, W. A., Hoencamp, E., Bouvy, P. F., & Haffmans, P. M. (1993). Reversible monoamine oxidase-A inhibitors in resistant major depression: Clinical Neuropharmacology Vol 16(Suppl 2) 1993, S69-S76.
  • Nolen, W. A., Hoencamp, E., Haffmans, P. M. J., & Bouvy, P. F. (1994). Classical and selective monoamine oxidase inhibitors in refractory major depression. Oxford, England: John Wiley & Sons.
  • Nolen, W. A., van den Broek, W. W., & Birkenhager, T. K. (2007). Treatment with low doses of tranylcypromine resulted in a disappointing remission rate: American Journal of Psychiatry Vol 164(3) Mar 2007, 524.
  • Nolen, W. A., Zohar, J., Roose, S. P., & Amsterdam, J. D. (1994). Refractory depression: Current strategies and future directions. Oxford, England: John Wiley & Sons.
  • Nunes, E. V., Deliyannides, D., Donovan, S., & McGrath, P. J. (1996). The management of treatment resistance in depressed patients with substance use disorders: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 311-327.
  • O'Reardon, J. P., & Amsterdam, J. D. (1998). Treatment-resistant depression: Progress and limitations: Psychiatric Annals Vol 28(11) Nov 1998, 633-640.
  • Orengo, C. A., Fullerton, L., & Kunik, M. E. (2005). Safety and Efficacy of Testosterone Gel 1% Augmentation in Depressed Men With Partial Response to Antidepressant Therapy: Journal of Geriatric Psychiatry and Neurology Vol 18(1) Mar 2005, 20-24.
  • Ostroff, R. B., & Nelson, J. C. (1999). Risperidone augmentation of selective serotonin reuptake inhibitors in major depression: Journal of Clinical Psychiatry Vol 60(4) Apr 1999, 256-259.
  • Padberg, F., Zwanzger, P., Keck, M. E., Kathmann, N., Mikhaiel, P., Ella, R., et al. (2002). Repetitive transcranial magnetic stimulation (rTMS) in major depression: Relation between efficacy and stimulation intensity: Neuropsychopharmacology Vol 27(4) Oct 2002, 638-645.
  • Padberg, F., Zwanzger, P., Thoma, H., Kathmann, N., Haag, C., Greenberg, B. D., et al. (1999). Repetitive transcranial magnetic stimulation (rTMS) in pharmocotherapy-refractory major depression: Comparative study of fast, slow and sham rTMS: Psychiatry Research Vol 88(3) Nov 1999, 163-171.
  • Papakostas, G. I. (2005). Augmentation of Standard Antidepressants with Atypical Antipsychotic Agents for Treatment-resistant Major Depressive Disorder: Directions in Psychiatry Vol 25(1) 2005, 1-12.
  • Papakostas, G. I., Petersen, T., Denninger, J., Sonawalla, S. B., Mahal, Y., Alpert, J. E., et al. (2003). Somatic symptoms in treatment-resistant depression: Psychiatry Research Vol 118(1) May 2003, 39-45.
  • Papakostas, G. I., Petersen, T., Iosifescu, D. V., Roffi, P. A., Alpert, J. E., Rosenbaum, J. F., et al. (2003). Axis III disorders in treatment-resistant major depressive disorder: Psychiatry Research Vol 118(2) May 2003, 183-188.
  • Papakostas, G. I., Petersen, T., Mischoulon, D., Hughes, M. E., Spector, A. R., Alpert, J. E., et al. (2003). Functioning and interpersonal relationships as predictors of response in treatment-resistant depression: Comprehensive Psychiatry Vol 44(1) Jan-Feb 2003, 44-50.
  • Papakostas, G. I., Petersen, T., Mischoulon, D., Ryan, J. L., Nierenberg, A. A., Bottiglieri, T., et al. (2004). Serum Folate, Vitamin B-sub-1-sub-2, and Homocysteine in Major Depressive Disorder, Part 1: Predictors of Clinical Response in Fluoxetine-Resistant Depression: Journal of Clinical Psychiatry Vol 65(8) Aug 2004, 1090-1095.
  • Papakostas, G. I., Petersen, T., Pava, J., Masson, E., Worthington, J. J., III, Alpert, J. E., et al. (2003). Hopelessness and Suicidal Ideation in Outpatients With Treatment- Resistant Depression: Prevalence and Impact on Treatment Outcome: Journal of Nervous and Mental Disease Vol 191(7) Jul 2003, 444-449.
  • Papakostas, G. I., Petersen, T., Sonawalla, S. B., Merens, W., Iosifescu, D. V., Alpert, J. E., et al. (2003). Serum cholesterol in treatment-resistant depression: Neuropsychobiology Vol 47(3) 2003, 146-151.
  • Papakostas, G. I., Petersen, T., Worthington, J. J., Roffi, P. A., Alpert, J. E., Fava, M., et al. (2003). A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed: International Clinical Psychopharmacology Vol 18(5) Sep 2003, 293-296.
  • Papakostas, G. I., Petersen, T. J., Farabaugh, A. H., Murakami, J. L., Pava, J. A., Alpert, J. E., et al. (2003). Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder: Journal of Clinical Psychiatry Vol 64(11) Nov 2003, 1357-1361.
  • Papakostas, G. I., Petersen, T. J., Green, C., Iosifescu, D. V., Yeung, A. S., Nierenberg, A. A., et al. (2005). A Description of Next-Step Switching Versus Augmentation Practices for Outpatients with Treatment-Resistant Major Depressive Disorder Enrolled in an Academic Specialty Clinic: Annals of Clinical Psychiatry Vol 17(3) Jul-Sep 2005, 161-165.
  • Papakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., III, Alpert, J. E., et al. (2005). Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment-Resistant Major Depressive Disorder: Journal of Clinical Psychiatry Vol 66(10) Oct 2005, 1326-1330.
  • Papakostas, G. I., Worthington, J. J., III, losifescu, D. V., Kinrys, G., Burns, A. M., Fisher, L. B., et al. (2006). The Combination of Duloxetine and Bupropion for Treatment-Resistant Major Depressive Disorder: Depression and Anxiety Vol 23(3) 2006, 178-181.
  • Papakostas, G. I., & Zarate, C. A., Jr. (2007). Novel Augmentation Strategies for Treatment-Resistant Major Depressive Disorder: Primary Psychiatry Vol 14(1) Jan 2007, 59-65.
  • Parker, G., & Watkins, T. (2002). Treatment-resistant depression: When antidepressant drug intolerance may indicate food intolerance: Australian and New Zealand Journal of Psychiatry Vol 36(2) Apr 2002, 263-265.
  • Parker, G. B., Malhi, G. S., Crawford, J. G., & Thase, M. E. (2005). Identifying 'paradigm failures' contributing to treatment-resistant depression: Journal of Affective Disorders Vol 87(2-3) Aug 2005, 185-191.
  • Patankar, T. F., Baldwin, R., Mitra, D., Jeffries, S., Sutcliffe, C., Burns, A., et al. (2007). Virchow-Robin space dilatation may predict resistance to antidepressant monotherapy in elderly patients with depression: Journal of Affective Disorders Vol 97(1-3) Jan 2007, 265-270.
  • Pathak, S., Johns, E. S., & Kowatch, R. A. (2005). Adjunctive Quetiapine for Treatment-Resistant Adolescent Major Depressive Disorder: A Case Series: Journal of Child and Adolescent Psychopharmacology Vol 15(4) Sep 2005, 696-702.
  • Patkar, A., Hill, K. P., Weinstein, S. P., & Schwartz, S. L. (2000). ECT in the presence of brain tumor and increased intracranial pressure: Evaluation and reduction of risk: Journal of ECT Vol 16(2) Jun 2000, 189-197.
  • Paykel, E. S. (1994). Epidemiology of refractory depression. Oxford, England: John Wiley & Sons.
  • Pazzaglia, P. J., Post, R. M., Ketter, T. A., Callahan, A. M., Marangell, L. B., Frye, M. A., et al. (1998). Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness: Journal of Clinical Psychopharmacology Vol 18(5) Oct 1998, 404-413.
  • Peet, M., & Horrobin, D. F. (2002). A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs: Archives of General Psychiatry Vol 59(10) Oct 2002, 913-920.
  • Perez, V., Soler, J., Puidgemont, D., Alvarez, E., & Artigas, F. (1999). A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors: Archives of General Psychiatry Vol 56(4) Apr 1999, 375-379.
  • Perlis, R. H., Iosifescu, D. V., Alpert, J., Nierenberg, A. A., Rosenbaum, J. F., & Fava, M. (2004). Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 45(3) May-Jun 2004, 224-229.
  • Perry, E. B., Jr., Berman, R. M., Sanacora, G., Anand, A., Lynch-Colonese, K., & Charney, D. S. (2004). Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: A double-blind, randomized, controlled trial: Journal of Clinical Psychiatry Vol 65(2) Feb 2004, 238-243.
  • Petersen, T., Gordon, J. A., Kant, A., Fava, M., Rosenbaum, J. F., & Nierenberg, A. A. (2001). Treatment resistant depression and Axis I co-morbidity: Psychological Medicine Vol 31(7) Oct 2001, 1223-1229.
  • Petersen, T., Hughes, M., Papakostas, G. I., Kant, A., Fava, M., Rosenbaum, J. F., et al. (2002). Treatment-resistant depression and Axis II comorbidity: Psychotherapy and Psychosomatics Vol 71(5) Sep-Oct 2002, 269-274.
  • Petersen, T., Papakostas, G. I., Mahal, Y., Guyker, W. M., Beaumont, E. C., Alpert, J. E., et al. (2004). Psychosocial functioning in patients with treatment resistant depression: European Psychiatry Vol 19(4) Jun 2004, 196-201.
  • Petersen, T., Papakostas, G. I., Posternak, M. A., Kant, A., Guyker, W. M., losifescu, D. V., et al. (2005). Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance: Journal of Clinical Psychopharmacology Vol 25(4) Aug 2005, 336-341.
  • Peterson, T. J., Feldman, G., Harley, R., Fresco, D. M., Graves, L., Holmes, A., et al. (2007). Extreme Response Style in Recurrent and Chronically Depressed Patients: Change With Antidepressant Administration and Stability During Continuation Treatment: Journal of Consulting and Clinical Psychology Vol 75(1) Feb 2007, 145-153.
  • Petrides, G., & Fink, M. (1996). Choosing a dosing strategy for electrical stimulation in ECT: Journal of Clinical Psychiatry Vol 57(10) Oct 1996, 487.
  • Pfeiffer, H., Scherer, J., & Aibus, M. (2004). High-dose L-thyroxine in therapy-resistant depression. Case analysis and catamnesis for quality control: Nervenarzt Vol 75(3) 2004, 242-248.
  • Phillips, K. A., & Nierenberg, A. A. (1994). The assessment and treatment of refractory depression: Journal of Clinical Psychiatry Vol 55(2, Suppl) Feb 1994, 20-26.
  • Pierre, J. M., & Gitlin, M. J. (2000). Bupropion-tranylcypromine combination for treatment-refractory depression: Journal of Clinical Psychiatry Vol 61(6) Jun 2000, 450-451.
  • Pilhatsch, M. K., Burghardt, R., Wandinger, K. P., Bauer, M., & Adli, M. (2006). Augmentation with atomoxetine in treatment-resistant depression with psychotic features: A case report: Pharmacopsychiatry Vol 39(2) Mar 2006, 79-80.
  • Pitchot, W., & Ansseau, M. (2001). Addition of olanzapine for treatment-resistant depression: American Journal of Psychiatry Vol 158(10) Oct 2001, 1737-1738.
  • Pluijms, E. M., Birkenhager, T. K., Huijbrechts, I. P. A. M., & Moleman, P. (2002). Influence of resistance to antidepressant pharmacotherapy on short-term response to electroconvulsive therapy: Journal of Affective Disorders Vol 69(1-3) May 2002, 93-99.
  • Pogarell, O., Ehrentraut, S., Ruther, T., Mulert, C., Hegerl, U., Moller, H. J., et al. (2005). Prolonged confusional state following electroconvulsive therapy--diagnostic clues from serial electroencephalography: Pharmacopsychiatry Vol 38(6) Nov 2005, 316-320.
  • Pogarell, O., Hegerl, U., & Mulert, C. (2006). Electroconvulsive Therapy and Nonconvulsive Status Epilepticus - Response to Anticonvulsants Might Solve the Dilemma: Pharmacopsychiatry Vol 39(3) May 2006, 120.
  • Poirier, M. F. (1999). The concept of resistant depression and therapeutic strategies, particularly with venlafaxine: L'Encephale Vol 25(Special Issue 2) Jun 1999, 55-57.
  • Poirier, M. F. (2000). "Drug treatment for resistant depression": Reply: British Journal of Psychiatry Vol 176 Apr 2000, 398.
  • Poirier, M. F., & Boyer, P. (1999). "Venlafaxine and paroxetin in treatment-resistant depression: Double-blind, randomised comparison": Erratum: British Journal of Psychiatry Vol 175 Oct 1999, 394.
  • Poirier, M. F., & Boyer, P. (1999). "Venlafaxine and paroxetine in treatment-resistant depression": Reply: British Journal of Psychiatry Vol 175 Dec 1999, 591.
  • Poirier, M. F., & Boyer, P. (1999). Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison: British Journal of Psychiatry Vol 175 Jul 1999, 12-16.
  • Pollock, B. G., Perel, J. M., Paradis, C. F., Fasiczka, A. L., & et al. (1994). Metabolic and physiologic consequences of nortriptyline treatment in the elderly: Psychopharmacology Bulletin Vol 30(2) 1994, 145-150.
  • Pope, H. G., Jr., Cohane, G. H., Kanayama, G., Siegel, A. J., & Hudson, J. I. (2003). Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial: American Journal of Psychiatry Vol 160(1) Jan 2003, 105-111.
  • Post, R. M., Ketter, T. A., Pazzaglia, P. J., Denicoff, K., Marangell, L., & George, M. S. (1994). Anticonvulsants in refractory mood disorders. Oxford, England: John Wiley & Sons.
  • Posternak, M. A., & Zimmerman, M. (2001). Switching versus augmentation: A prospective, naturalistic comparison in depressed, treatment-resistant patients: Journal of Clinical Psychiatry Vol 62(2) Feb 2001, 135-142.
  • Potter, W. Z., & Manji, H. K. (1994). Dopaminergic drugs and systems in refractory depression. Oxford, England: John Wiley & Sons.
  • Potter, W. Z., & Manji, H. K. (1994). Refractory depression: Is there a next step? : Psychiatric Annals Vol 24(10) Oct 1994, 505-507.
  • Preskorn, S. H. (2002). Polypharmacy in a patient with refractory major depression. Part I: The case: Journal of Psychiatric Practice Vol 8(6) Nov 2002, 370-376.
  • Preskorn, S. H. (2003). Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management: Journal of Psychiatric Practice Vol 9(1) Jan 2003, 71-78.
  • Price, L. H., Lemmond, K., & Carpenter, L. L. (2000). Refractory depression: Assessment and treatment. Long Island City, NY: Hatherleigh Company.
  • Pridmore, S., Bruno, R., Turnier-Shea, Y., Reid, P., & Rybak, M. (2000). Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode: International Journal of Neuropsychopharmacology Vol 3(2) Jun 2000, 129-134.
  • Pridmore, S., & Turnier-Shea, Y. (2004). Medication options in the treatment of treatment-resistant depression: Australian and New Zealand Journal of Psychiatry Vol 38(4) Apr 2004, 219-225.
  • Prudic, J., Haskett, R. F., Mulsant, B., Malone, K. M., & et al. (1996). Resistance to antidepressant medications and short-term clinical response to ECT: American Journal of Psychiatry Vol 153(8) Aug 1996, 985-992.
  • Prudic, J., & Sackeim, H. A. (1997). "Resistance to antidepressant medications and short-term clinical response to ECT": Reply: American Journal of Psychiatry Vol 154(5) May 1997, 722.
  • Prudic, J. M., Sackeim, H. A., & Rifas, S. (1994). Medication resistance, response to ECT, and prevention of relapse: Psychiatric Annals Vol 24(5) May 1994, 228-231.
  • Puri, B. K., Counsell, S. J., Richardson, A. J., & Horrobin, D. F. (2002). Eicosapentaenoic acid in treatment-resistant depression: Archives of General Psychiatry Vol 59(1) Jan 2002, 91-92.
  • Puzynski, S., Koszewska, I., Kalinowski, A., Bogdanowicz, E., & et al. (1993). Drug-resistance in endogenous depression: I. Refractoriness to antidepressants in patients with depression firstly admitted to a psychiatric clinic: Psychiatria Polska Vol 27(6) Nov-Dec 1993, 673-682.
  • Puzynski, S., Koszewska, I., Kalinowski, A., Bogdanowicz, E., & et al. (1994). Drug-resistance in endogenous depression: II. Refractoriness to antidepressants in the course of affective disorders: Psychiatria Polska Vol 28(1) Jan-Feb 1994, 5-15.
  • Puzynski, S., Koszewska, I., Kalinowski, A., Bogdanowicz, E., & et al. (1995). Drug-resistance in endogenous depression: I. Refractoriness to antidepressants in patients with depression firstly admitted to a psychiatric clinic: Psychiatria Polska Vol 29(3, Suppl) May-Jun 1995, 95-103.
  • Puzynski, S., Koszewska, I., Kalinowski, A., Bogdanowicz, E., & et al. (1995). Drug-resistance in endogenous depression: II. Refractoriness to antidepressants in the course of affective disorders: Psychiatria Polska Vol 29(3, Suppl) May-Jun 1995, 105-114.
  • Quitkin, F., McGrath, P. J., Stewart, J. W., Ocepek-Welikson, K., Taylor, B. P., Nunes, E., et al. (1996). Chronological milestones to guide drug change: When should clinicians switch antidepressants? : Archives of General Psychiatry Vol 53(9) Sep 1996, 785-792.
  • Rado, J., & Janicak, P. G. (2007). Vagus nerve stimulation for severe depression: Journal of Psychosocial Nursing & Mental Health Services Vol 45(7) Jul 2007, 43-51.
  • Ranen, N. G., Peyser, C. E., & Folstein, S. E. (1994). ECT as a treatment of depression in Huntington's disease: Journal of Neuropsychiatry & Clinical Neurosciences Vol 6(2) Spr 1994, 154-159.
  • Ranjan, R., & Meltzer, H. Y. (1996). Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression: Biological Psychiatry Vol 40(4) Aug 1996, 253-258.
  • Rao, M. L., Deister, A., Laux, G., Staberock, U., & et al. (1996). Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse: Pharmacopsychiatry Vol 29(3) May 1996, 97-102.
  • Rapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., et al. (2006). Corrigendum: Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation: Neuropsychopharmacology Vol 31(11) Nov 2006, 2514.
  • Rapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., et al. (2006). Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation: Neuropsychopharmacology Vol 31(11) Nov 2006, 2505-2513.
  • Rapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., et al. (2007). Corrigendum: "Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation": Neuropsychopharmacology Vol 32(5) May 2007, 1208.
  • Rasmussen, N.-A., Schroder, P., Olsen, L. R., Brodsgaard, M., Unden, M., & Bech, P. (2005). Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92): Nordic Journal of Psychiatry Vol 59(3) Jun 2005, 173-178.
  • Reus, V. I. (1996). Management of treatment-resistant unipolar and chronically depressed patients: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 201-213.
  • Reynaert-Dupuis, C., Zdanowicz, N., Leyman, S., Mignon, A., & Seghers, S. (2002). Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment: Primary Care Psychiatry Vol 8(2) Jun 2002, 63-68.
  • Rocha, F. L., & Hara, C. (2003). Lamotrigine augmentation in unipolar depression: International Clinical Psychopharmacology Vol 18(2) Mar 2003, 97-99.
  • Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007). Creatine monohydrate in resistant depression: A preliminary study: Bipolar Disorders Vol 9(7) Nov 2007, 754-758.
  • Romildo Bueno, J. (1991). Pharmacologic treatment of resistant depression: Use of fluoxetine with or in place of therapy: Jornal Brasileiro de Psiquiatria Vol 40(3) Apr 1991, 133-136.
  • Roose, S. P. (1994). Selective serotonin reuptake inhibitors in refractory depression. Oxford, England: John Wiley & Sons.
  • Ros, S., Aguera, L., de la Gandara, J., Rojo, J. E., & de Pedro, J. M. (2005). Potentiation strategies for treatment-resistant depression: Acta Psychiatrica Scandinavica Vol 112(Suppl428) Nov 2005, 14-24.
  • Rosa, M. A., Gattaz, W. F., Pascual-Leone, A., Fregni, F., Rosa, M. O., Rumi, D. O., et al. (2006). Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: A randomized, single-blind study: International Journal of Neuropsychopharmacology Vol 9(6) Dec 2006, 667-676.
  • Rosenbaum, J. F., & Fredman, S. J. (1999). Pramipexole treatment for cocaine cravings: American Journal of Psychiatry Vol 156(11) Nov 1999, 1834.
  • Rosenbaum, J. F., & Heninger, G. (2000). Vagus nerve stimulation for treatment-resistant depression: Biological Psychiatry Vol 47(4) Feb 2000, 273-275.
  • Rossini, D., Lucca, A., Zanardi, R., Magri, L., & Smeraldi, E. (2005). Transcranial magnetic stimulation in treatment-resistant depressed patients: A double-blind, placebo-controlled trial: Psychiatry Research Vol 137(1-2) Nov 2005, 1-10.
  • Rothschild, A. J. (1996). Management of psychotic, treatment-resistant depression: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 237-252.
  • Rothschild, B. S. (1994). Fluoxetine-nortriptyline therapy of treatment-resistant major depression in a geriatric patient: Journal of Geriatric Psychiatry and Neurology Vol 7(3) Jul-Sep 1994, 137-138.
  • Rouillon, F., & Gorwood, P. (1998). The use of lithium to augment antidepressant medication: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 32-41.
  • Rubin, N. I., & Arceneaux, J. M. (2001). Intractable depression or psychosis: Acta Psychiatrica Scandinavica Vol 104(5) Nov 2001, 402-405.
  • Rubio, G., San, L., Lopez-Munoz, F., & Alamo, C. (2004). Reboxetine adjunct for partial or nonresponders to antidepressant treatment: Journal of Affective Disorders Vol 81(1) 2004, 67-72.
  • Rubio, G., San, L., Lopez-Munoz, F., Garcia-Garcia, E., & Alamo, C. (2003). Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors: Actas Espanolas de Psiquiatria Vol 31(6) Nov-Dec 2003, 315-324.
  • Rudas, S., Schmitz, M., Pichler, P., & Baumgartner, A. (1999). Treatment of refractory chronic depression and dysthymia with high-dose thyroxine: Biological Psychiatry Vol 45(2) Jan 1999, 229-233.
  • Ruiz, M., Vairo, M. C., Matusevich, D., & Finkelsztein, C. (2005). Treatment-Resistant Depression: Personality versus Bipolar Disorders. Bibliography Review with a Clinical Case Report. Hauppauge, NY: Nova Science Publishers.
  • Rush, A. J., & George, M. S. (2006). "Responding to three articles regarding vagus nerve stimulation (VNS) for depression": Reply: Biological Psychiatry Vol 60(12) Dec 2006, 1382-1383.
  • Rush, A. J., George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Giller, C., et al. (2000). Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study: Biological Psychiatry Vol 47(4) Feb 2000, 276-286.
  • Rush, A. J., Marangell, L. B., Sackeim, H. A., George, M. S., Brannan, S. K., Davis, S. M., et al. (2005). Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial: Biological Psychiatry Vol 58(5) Sep 2005, 347-354.
  • Rush, A. J., Sackeim, H. A., Marangell, L. B., George, M. S., Brannan, S. K., Davis, S. M., et al. (2005). Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study: Biological Psychiatry Vol 58(5) Sep 2005, 355-363.
  • Russell, J. L. (1996). Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression: Journal of Clinical Psychopharmacology Vol 16(1) Feb 1996, 35-37.
  • Russell, J. M., Hawkins, K., Ozminkowski, R. J., Orsini, L., Crown, W. H., Kennedy, S., et al. (2004). The Cost Consequences of Treatment-Resistant Depression: Journal of Clinical Psychiatry Vol 65(3) Mar 2004, 341-347.
  • Rutherford, B., Sneed, J., Miyazaki, M., Eisenstadt, R., Devanand, D., Sackeim, H., et al. (2007). An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression: International Journal of Geriatric Psychiatry Vol 22(10) Oct 2007, 986-991.
  • Rybakowski, J. K., Suwalska, A., & Chlopocka-Wozniak, M. (1999). Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression: Neuropsychobiology Vol 40(3) Sep 1999, 134-139.
  • Sachdev, P. S., & Sachdev, J. (2005). Long-term outcome of neurosurgery for the treatment of resistant depression: Journal of Neuropsychiatry & Clinical Neurosciences Vol 17(4) Fal 2005, 478-485.
  • Sachs, G. S. (1996). Treatment-resistant bipolar depression: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 215-236.
  • Sackeim, H. A. (2001). The definition and meaning of treatment-resistant depression: Journal of Clinical Psychiatry Vol 62(Suppl16) 2001, 10-17.
  • Sackeim, H. A., Brannan, S. K., Rush, A. J., George, M. S., Marangell, L. B., & Allen, J. (2007). Durability of antidepressant response to vagus nerve stimulation (VNSTM): International Journal of Neuropsychopharmacology Vol 10(6) Dec 2007, 817-826.
  • Sackeim, H. A., Keilp, J. G., Rush, A. J., George, M. S., Marangell, L. B., Dormer, J. S., et al. (2001). The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression: Neuropsychiatry, Neuropsychology, & Behavioral Neurology Vol 14(1) Jan 2001, 53-62.
  • Sackeim, H. A., & Lisanby, S. H. (2001). Physical treatments in psychiatry: Advances in electroconvulsive therapy, transcranial magnetic stimulation, and vagus nerve stimulation. Washington, DC: American Psychiatric Publishing, Inc.
  • Sackeim, H. A., Rush, A. J., George, M. S., Marangell, L. B., Husain, M. M., Nahas, Z., et al. (2001). Vagus nerve stimulation (VNS-super(TM)) for treatment-resistant depression: Efficacy, side effects, and predictors of outcome: Neuropsychopharmacology Vol 25(5) Nov 2001, 713-728.
  • Sagud, M., Mihaljevic-Peles, A., Muck-Seler, D., Jakovljevic, M., & Pivac, N. (2006). Quetiapine augmentation in treatment-resistant depression: A naturalistic study: Psychopharmacology Vol 187(4) Sep 2006, 511-514.
  • Sajatovic, M., DiGiovanni, S., Fuller, M., Belton, J., DeVega, E., Marqua, S., et al. (1999). Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity: Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy Vol 21(4) Apr 1999, 733-740.
  • Sakauye, K., Berry, T., & Gremillion, P. (2003). Postictal deliriuum after right-unilateral electroconvulsive therapy caused by non-prototypical hemispheric asymmetry: American Journal of Geriatric Psychiatry Vol 11(4) Jul-Aug 2003, 469.
  • Salzman, C. (1994). Clinical and research issues concerning therapy-resistant depression: Integrative Psychiatry Vol 10(2) 1994, 90-91.
  • Sanacora, G., Kendell, S. F., Fenton, L., Coric, V., & Krystal, J. H. (2004). Riluzole augmentation for treatment-resistant depression: American Journal of Psychiatry Vol 161(11) Nov 2004, 2132.
  • Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., et al. (2007). Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms: Biological Psychiatry Vol 61(6) Mar 2007, 822-825.
  • Sanacora, G., Mason, G. F., Rothman, D. L., Hyder, F., Ciarcia, J. J., Ostroff, R. B., et al. (2003). Increased cortical GABA concentrations in depressed patients receiving ECT: American Journal of Psychiatry Vol 160(3) Mar 2003, 577-579.
  • Santos, M. A., Hara, C., Stumpf, B. L. P., & Rocha, F. L. (2006). Treatment-resistant depression: Review of pharmacologic antidepressant strategies: Jornal Brasileiro de Psiquiatria Vol 55(3) Jul-Sep 2006, 232-242.
  • Scanlan, J. M. (2007). Comments on "A note on the partnership between psychiatry and primary care." American Journal of Psychiatry Vol 164(3) Mar 2007, 528.
  • Schaffer, A., Levitt, A. J., & Joffe, R. T. (2000). Mexiletine in treatment-resistant bipolar disorder: Journal of Affective Disorders Vol 57(1-3) Jan-Mar 2000, 249-253.
  • Schening, L. J. (2004). Refractory depression treatment options: A meta-analysis. Dissertation Abstracts International: Section B: The Sciences and Engineering.
  • Schindler, F., & Anghelescu, I. G. (2007). Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: A randomized, open-label study: International Clinical Psychopharmacology Vol 22(3) May 2007, 179-182.
  • Schlaepfer, T. E., Cohen, M. X., Frick, C., Kosel, M., Brodesser, D., Axmacher, N., et al. (2008). Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression: Neuropsychopharmacology Vol 33(2) Jan 2008, 368-377.
  • Schmauss, M., & Messer, T. (2007). Augmentation strategies for therapy resistant depression: A review: Psychiatrische Praxis Vol 34(4) May 2007, 165-174.
  • Schmidt, E. Z., Reininghaus, B., Enzinger, C., Ebner, C., Hofmann, P., & Kapfhammer, H. P. (2008). Changes in brain metabolism after ECT--Positron emission tomography in the assessment of changes in glucose metabolism subsequent to electroconvulsive therapy--Lessons, limitations and future applications: Journal of Affective Disorders Vol 106(1-2) Feb 2008, 203-208.
  • Schopf, J., & Lemarchand, T. (1994). Lithium addition in endogenous depressions resistant to tricyclic antidepressants or related drugs: Relation to the status of the pituitary-thyroid axis: Pharmacopsychiatry Vol 27(5) Sep 1994, 198-201.
  • Schouten, E. A., D'Alfonso, A. A., Nolen, W. A., de Haan, E. H., Wijkstra, J., & Kahn, R. S. (1999). Small effect of rapid rate transcranial magnetic stimulation on antidepressant free outpatients with a depressive disorder: Tijdschrift voor Psychiatrie Vol 41(4) 1999, 233-237.
  • Schweitzer, I., Burrows, G., Tuckwell, V., Polonowita, A., Flynn, P., George, T., et al. (2001). Sustained response to open-label venlafaxine in drug-resistant major depression: Journal of Clinical Psychopharmacology Vol 21(2) Apr 2001, 185-189.
  • Schweitzer, I., Tuckwell, V., & Johnson, G. (1997). A review of the use of augmentation therapy for the treatment of resistant depression: Implications for the clinician: Australian and New Zealand Journal of Psychiatry Vol 31(3) Jun 1997, 340-352.
  • Scocco, P., & Frank, E. (2002). Interpersonal psychotherapy as augmentation treatment in depressed elderly responding poorly to antidepressant drugs: A case series: Psychotherapy and Psychosomatics Vol 71(6) Nov-Dec 2002, 357-361.
  • Scott, J. (1994). Predictors of non-response to antidepressants. Oxford, England: John Wiley & Sons.
  • Seidman, S. N., Miyazaki, M., & Roose, S. P. (2005). Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: Randomized placebo-controlled clinical trial: Journal of Clinical Psychopharmacology Vol 25(6) Dec 2005, 584-588.
  • Seidman, S. N., & Rabkin, J. G. (1998). Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression: Journal of Affective Disorders Vol 48(2-3) Mar 1998, 157-161.
  • Serby, M. (2003). Methylphemdate-Induced Obsessive-Compulsive Symptoms in an Elderly Man: CNS Spectrums Vol 8(8) Aug 2003, 612-613.
  • Shah, P. J., Ebmeier, K. P., Glabus, M. F., & Goodwin, G. M. (1998). Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression: Controlled magnetic resonance imaging study: British Journal of Psychiatry Vol 172(6) Jun 1998, 527-532.
  • Shah, P. J., Glabus, M. F., Goodwin, G. M., & Ebmeier, K. P. (2002). Chronic, treatment-resistant depression and right fronto-striatal atrophy: British Journal of Psychiatry Vol 180(5) May 2002, 434-440.
  • Shapira, B., & Lerer, B. (1996). "Choosing a dosing strategy for electrical stimulation in ECT". Reply: Journal of Clinical Psychiatry Vol 57(10) Oct 1996, 487-488.
  • Shapira, B., Lidsky, D., Gorfine, M., & Lerer, B. (1996). Electroconvulsive therapy and resistant depression: Clinical implications of seizure threshold: Journal of Clinical Psychiatry Vol 57(1) Jan 1996, 32-38.
  • Shapira, N. A., Verduin, M. L., & DeGraw, J. D. (2001). Treatment of refractory major depression with tramadol monotherapy: Journal of Clinical Psychiatry Vol 62(3) Mar 2001, 205-206.
  • Sharma, V. (2001). Loss of response to antidepressants and subsequent refractoriness: Diagnostic issues in a retrospective case series: Journal of Affective Disorders Vol 64(1) Apr 2001, 99-106.
  • Sharma, V., Khan, M., & Smith, A. (2005). A closer look at treatment resistant depression: Is it due to a bipolar diathesis? : Journal of Affective Disorders Vol 84(2-3) Feb 2005, 251-257.
  • Sharma, V., Mazmanian, D., Persad, E., & Kueneman, K. (1995). A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 40(5) Jun 1995, 270-274.
  • Sharma, V., & Persad, E. (1994). Pharmacotherapy of rapid cycling bipolar disorder: A review: Lithium Vol 5(3) Aug 1994, 117-125.
  • Sharma, V., Persad, E., Kueneman, K., Mazmanian, D., & et al. (1994). Lithium augmentation of valproic acid in treatment resistent depression: Lithium Vol 5(2) May 1994, 99-103.
  • Sharpley, A. L., Bhagwagar, Z., Hafizi, S., Whale, W. R., Gijsman, H. J., & Cowen, P. J. (2003). Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients: Journal of Clinical Psychiatry Vol 64(2) Feb 2003, 192-196.
  • Shelton, R. C. (1992). Review of Treatment Strategies for Refractory Depression: PsycCRITIQUES Vol 37 (2), Feb, 1992.
  • Shelton, R. C. (1999). Mood-stabilizing drugs in depression: Journal of Clinical Psychiatry Vol 60(Suppl 5) 1999, 37-40.
  • Shelton, R. C. (1999). Treatment options for refractory depression: Journal of Clinical Psychiatry Vol 60(Suppl 4) 1999, 57-63.
  • Shelton, R. C. (2002). Dr. Shelton Replies: American Journal of Psychiatry Vol 159(1) Jan 2002, 155-156.
  • Shelton, R. C. (2003). The use of antidepressants in novel combination therapies: Journal of Clinical Psychiatry Vol 64(Suppl2) 2003, 14-18.
  • Shelton, R. C. (2006). Management of Major Depressive Disorder Following Failure of First Antidepressant Treatment: Primary Psychiatry Vol 13(4) Apr 2006, 73-82.
  • Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., et al. (2001). A novel augmentation strategy for treating resistant major depression: American Journal of Psychiatry Vol 158(1) Jan 2001, 131-134.
  • Shelton, R. C., & Tomarken, A. J. (2001). Can recovery from depression be achieved? : Psychiatric Services Vol 52(11) Nov 2001, 1469-1478.
  • Shelton, R. C., Williamson, D. J., Corya, S. A., Sanger, T. M., Van Campen, L. E., Case, M., et al. (2005). Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance: Journal of Clinical Psychiatry Vol 66(10) Oct 2005, 1289-1297.
  • Shergill, S. S., & Katona, C. L. E. (1997). Pharmacological choices after one antidepressant fails: A survey of UK psychiatrists: Journal of Affective Disorders Vol 43(1) Mar 1997, 19-25.
  • Shergill, S. S., Robertson, M. M., Stein, G., Bernadt, M., & Katona, C. L. E. (1999). Outcome in refractory depression: Journal of Affective Disorders Vol 54(3) Aug 1999, 287-294.
  • Silverstone, P. H., & Birkett, L. (2000). Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: A retrospective study: Journal of Psychiatry & Neuroscience Vol 25(3) May 2000, 276-280.
  • Simon, J. S., & Nemeroff, C. B. (2005). Aripiprazole Augmentation of Antidepressants for the Treatment of Partially Responding and Nonresponding Patients With Major Depressive Disorder: Journal of Clinical Psychiatry Vol 66(10) Oct 2005, 1216-1220.
  • Simpson, S., Baldwin, R. C., Jackson, A., & Burns, A. S. (1998). Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression: Psychological Medicine Vol 28(5) Sep 1998, 1015-1026.
  • Singh, J., Zarate, C. A., & Krystal, A. D. (2004). Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine: Psychopharmacology Vol 173(1-2) Apr 2004, 227-228.
  • Sintzel, F., Mallaret, M., & Bougerol, T. (2004). Potentializing of tricyclics and serotoninergics by thyroid hormones in resistant depressive disorders: L'Encephale Vol 30(3) May-Jun 2004, 267-275.
  • Skarsater, I., Dencker, K., & Agren, H. (1999). The experience of social support in patients suffering from treatment-refractory depression--A pilot study: Archives of Psychiatric Nursing Vol 13(2) Apr 1999, 89-96.
  • Sluzewska, A., Samborski, W., Sobieska, M., Klein, R., Bosmans, E., & Rybakowski, J. K. (1997). Serotonin antibodies in relation to immune activation in major depression: Human Psychopharmacology: Clinical and Experimental Vol 12(5) Sep-Oct 1997, 453-458.
  • Sluzewska, A., Sobieska, M., & Rybakowski, J. K. (1997). Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression: Neuropsychobiology Vol 35(3) Apr 1997, 123-127.
  • Sokolski, K. N., Conney, J. C., Brown, B. J., & DeMet, E. M. (2004). Once-daily high-dose pindolol for SSRI-refractory depression: Psychiatry Research Vol 125(2) Feb 2004, 81-86.
  • Sonino, N., & Fava, G. A. (2003). Tolerance to antidepressant treatment may be overcome by ketconazole. Report of two cases: Journal of Psychiatric Research Vol 37(2) Mar-Apr 2003, 171-173.
  • Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., et al. (1999). Treatment resistant depression: Methodological overview and operational criteria: European Neuropsychopharmacology Vol 9(1-2) Jan 1999, 83-91.
  • Souery, D., & Mendlewicz, J. (1998). Compliance and therapeutic issues in resistant depression: International Clinical Psychopharmacology Vol 13(Suppl 2) Feb 1998, S13-S18.
  • Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study: Journal of Clinical Psychiatry Vol 68(7) Jul 2007, 1062-1070.
  • Souery, D., Oswald, P., & Zohar, J. (2005). Treatment-Resistant Mood Disorders: from Diagnosis to Treatment. New York, NY: John Wiley & Sons Ltd.
  • Souery, D., & Van der Auwera, K. (2004). The Multiple Facets of Treatment-Resistant Depression: CNS Spectrums Vol 9(11,Suppl12) Nov 2004, 803-807.
  • Soutullo, C. A., Sorter, M. T., Foster, K. D., McElroy, S. L., & Keck, P. E. (1999). Olanzapine in the treatment of adolescent acute mania: A report of seven cases: Journal of Affective Disorders Vol 53(3) Jun 1999, 279-283.
  • Sperling, W., Kornhuber, J., Wiltfang, J., & Bleich, S. (2007). Combined VNS - rTMS treatment in a patient with therapy resistant depression: Pharmacopsychiatry Vol 40(1) Jan 2007, 39-40.
  • Spoov, J., & Lahdelma, L. (1998). Should thyroid augmentation precede lithium augmentation: A pilot study: Journal of Affective Disorders Vol 49(3) Jun 1998, 235-239.
  • Sprenger, D. (1997). Buspirone augmentation of a selective serotonin reuptake inhibitor: Efficacy in two depressed patients with comorbid anxiety and Type 1 alcohol dependence: Journal of Clinical Psychopharmacology Vol 17(5) Oct 1997, 425-426.
  • Stahl, S. M. (1997). Antidepressant combinations and augmentation strategies for difficult cases, Part 1: The serotonin strategy versus the classic strategies: Psychiatric Annals Vol 27(10) Oct 1997, 657-660.
  • Staley, C. J. (1994). Case report 5: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 369.
  • Staller, J. A. (2003). Chronic complex depression: Psychiatric Services Vol 54(6) Jun 2003, 771.
  • Stanford, A. D., Husain, M. M., Luber, B. M., Berman, R., Truesdale, M. D., McClintock, S., et al. (2005). Magnetic seizure therapy and other convulsive therapies: Primary Psychiatry Vol 12(10) Oct 2005, 44-50.
  • Steffens, D. C., Krystal, A. D., Sibert, T. E., Moore, S. D., & et al. (1995). Cost effectiveness of maintenance ECT: Convulsive Therapy Vol 11(4) Dec 1995, 283-284.
  • Stern, L., Hirschmann, S., & Grunhaus, L. (1997). ECT in patients with major depressive disorder and low cardiac output: Convulsive Therapy Vol 13(2) Jun 1997, 68-73.
  • Stewart, J. W., Bruder, G. E., McGrath, P. J., & Quitkin, F. M. (2003). Do age of onset and course of illness define biologically distinct groups within atypical depression? : Journal of Abnormal Psychology Vol 112(2) May 2003, 253-262.
  • Stimpson, N., Agrawal, N., & Lewis, G. (2002). Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: Systematic review: British Journal of Psychiatry Vol 181(4) Oct 2002, 284-294.
  • Stoudemire, A., Hill, C. D., Morris, R., & Lewison, B. J. (1993). Long-term outcome of treatment-resistant depression in older adults: American Journal of Psychiatry Vol 150(10) Oct 1993, 1539-1540.
  • Strober, M., Pataki, C., & DeAntonio, M. (1998). Complete remission of "treatment resistant" severe melancholia in adolescents with phenelzine: Two case reports: Journal of Affective Disorders Vol 50(1) Jul 1998, 55-58.
  • Strober, M., Rao, U., DeAntonio, M., Liston, E., State, M., Amaya-Jackson, L., et al. (1998). Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy: Biological Psychiatry Vol 43(5) Mar 1998, 335-338.
  • Stryjer, R., Strous, R. D., Shaked, G., Bar, F., Feldman, B., Kotler, M., et al. (2003). Amantadine as augmentation therapy in the management of treatment-resistant depression: International Clinical Psychopharmacology Vol 18(2) Mar 2003, 93-96.
  • Stubbeman, W. F., Leuchter, A. F., Cook, I. A., Shurman, B. D., Morgan, M., Gunay, I., et al. (2004). Pretreatment neurophysiologic function and ECT response in depression: Journal of ECT Vol 20(3) Sep 2004, 142-144.
  • Su, T.-P., Huang, C.-C., & Wei, I. H. (2005). Add-On rTMS for Medication-Resistant Depression: A Randomized, Double-Blind, Sham-Controlled Trial in Chinese Patients: Journal of Clinical Psychiatry Vol 66(7) Jul 2005, 930-937.
  • Sunderland, T., Cohen, R. M., Molchan, S. E., Lawlor, B. A., & et al. (1994). High-dose selegiline in treatment-resistant older depressive patients: Archives of General Psychiatry Vol 51(8) Aug 1994, 607-615.
  • Sussman, N. (1998). Anxiolytic antidepressant augmentation: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 42-50.
  • Sussman, N. (2005). Commentary on Treatment-Resistant Depression: Primary Psychiatry Vol 12(2) Feb 2005, 13.
  • Sussman, N. (2007). The Sequenced Treatment Alternatives to Relieve Depression Study: Recent results: Primary Psychiatry Vol 14(2) Feb 2007, 31-34.
  • Sussman, N., & Joffe, R. T. (1998). Antidepressant augmentation: Conclusions and recommendations: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 70-73.
  • Swan, J., Sorrell, E., MacVicar, B., Durham, R., & Matthews, K. (2004). "Coping with depression": An open study of the efficacy of a group psychoeducational intervention in chronic, treatment-refractory depression: Journal of Affective Disorders Vol 82(1) Oct 2004, 125-129.
  • Swiecicki, L. (2003). Efficacy of citalopram in more than maximal dose in drug-resistant depression. Case report: Psychiatria Polska Vol 37(5) Sep-Oct 2003, 839-844.
  • Tanghe, A., Steeman, J., Bollen, E., van Renynghe de Voxvrie, G., Dendooven, M., & Haazen, L. (1997). Moclobeminde and amitriptyline, alone or in combination, in therapy resistant depression: Human Psychopharmacology: Clinical and Experimental Vol 12(5) Sep-Oct 1997, 509-510.
  • Tanum, L. H. (1994). Combination treatment with antidepressants in refractory depression: International Clinical Psychopharmacology Vol 9(Suppl 2) Jun 1994, 37-40.
  • Tauscher, J., Neumeister, A., Fischer, P., Frey, R., & Kasper, S. (1997). Electroconvulsive therapy in the clinical practice: Nervenarzt Vol 68(5) May 1997, 410-416.
  • Taylor, D. (2005). Looking at the clinical problem of chronic, refractory or "treatment-resistant" depression: Psyche: Zeitschrift fur Psychoanalyse und ihre Anwendungen Vol 59(9-10) Sep-Oct 2005, 843-863.
  • Taylor, F. B., & Prather, M. R. (2003). The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder: Depression and Anxiety Vol 18(2) 2003, 83-88.
  • Tew, J. D., Jr., Mulsant, B. H., Haskett, R. F., Dolata, D., Hixson, L., & Mann, J. J. (2002). A randomized comparison of high-charge right unilateral electroconvulsive therapy and bilateral electroconvulsive therapy in older depressed patients who failed to respond to 5 to 8 moderate-charge right unilateral treatments: Journal of Clinical Psychiatry Vol 63(12) Dec 2002, 1102-1105.
  • Thase, M. E. (1994). The roles of psychosocial factors and psychotherapy in refractory depression: Missing pieces in the puzzle of treatment resistance? Oxford, England: John Wiley & Sons.
  • Thase, M. E. (1996). The role of Axis II comorbidity in the management of patients with treatment-resistant depression: Psychiatric Clinics of North America Vol 19(2) Jun 1996, 287-309.
  • Thase, M. E. (2001). The need for clinically relevant research on treatment-resistant depression: Journal of Clinical Psychiatry Vol 62(4) Apr 2001, 221-224.
  • Thase, M. E. (2002). What role do atypical antipsychotic drugs have in treatment-resistant depression? : Journal of Clinical Psychiatry Vol 63(2) Feb 2002, 95-103.
  • Thase, M. E. (2003). Therapeutic Alternatives for Difficult-to-treat Depression: What is the State of the Evidence? : Psychiatric Annals Vol 33(12) Dec 2003, 813-821.
  • Thase, M. E. (2004). Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence: CNS Spectrums Vol 9(11,Suppl12) Nov 2004, 808-821.
  • Thase, M. E. (2005). Pharmacologic Strategies for Treatment-resistant Depression: An update on the State of the Evidence: Psychiatric Annals Vol 35(12) Dec 2005, 970-978.
  • Thase, M. E. (2006). Treatment-Resistant Depression and the Bipolar Spectrum: Recognition and Management: Primary Psychiatry Vol 13(11) Nov 2006, 59-67.
  • Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., et al. (2007). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder: Journal of Clinical Psychiatry Vol 68(2) Feb 2007, 224-236.
  • Thase, M. E., Friedman, E. S., & Howland, R. H. (2001). Management of treatment-resistant depression: Psychotherapeutic perspectives: Journal of Clinical Psychiatry Vol 62(Suppl18) 2001, 18-24.
  • Thase, M. E., & Howland, R. H. (1994). Refractory depression: Relevance of psychosocial factors and therapies: Psychiatric Annals Vol 24(5) May 1994, 232-240.
  • Thase, M. E., Howland, R. H., & Friedman, E. S. (1998). Treating antidepressant nonresponders with augmentation strategies: An overview: Journal of Clinical Psychiatry Vol 59(Suppl 5) 1998, 5-15.
  • Thomas, A., & Taylor, D. (2003). Evaluating the relationship of high-dose venlafaxine prescribing to treatment-resistant depression: Psychiatric Bulletin Vol 27(3) Mar 2003, 93-95.
  • Thomas, R. (1994). Case report 6: Human Psychopharmacology: Clinical and Experimental Vol 9(5) Sep-Oct 1994, 369-370.
  • Tohen, M., & Gannon, K. S. (1998). Pharmacologic approaches for treatment-resistant mania: Psychiatric Annals Vol 28(11) Nov 1998, 629-632.
  • Trivedi, M. H. (2003). Treatment-resistant depression: New therapies on the horizon: Annals of Clinical Psychiatry Vol 15(1) Mar 2003, 59-70.
  • Trivedi, M. H., & Kleiber, B. A. (2001). Using treatment algorithms for the effective management of treatment-resistant depression: Journal of Clinical Psychiatry Vol 62(Suppl18) 2001, 25-29.
  • Tsai, G. E. (2007). Searching for rational anti-N-methyl-D-aspartate treatment for depression: Archives of General Psychiatry Vol 64(9) Sep 2007, 1099-1100.
  • Tulen, J. H. M., Volkers, A. C., van den Broek, W. W., & Bruijn, J. A. (2006). Sustained Effects of Phenelzine and Tranylcypromine on Orthostatic Challenge in Antidepressant-refractory Depression: Journal of Clinical Psychopharmacology Vol 26(5) Oct 2006, 542-544.
  • Turnier-Shea, Y., Bruno, R., & Pridmore, S. (2006). Daily and spaced treatment with transcranial magnetic stimulation in major depression: A pilot study: Australian and New Zealand Journal of Psychiatry Vol 40(9) Sep 2006, 759-763.
  • Uhr, M., Grauer, M. T., & Holsboer, F. (2003). Differential Enhancement of Antidepressant Penetration into the Brain in Mice with abcb1ab (mdr1ab) P-Glycoprotein Gene Disruption: Biological Psychiatry Vol 54(8) Oct 2003, 840-846.
  • Valenstein, M. (2006). Keeping Our Eyes on STAR*D: American Journal of Psychiatry Vol 163(9) Sep 2006, 1484-1486.
  • Valenstein, M., McCarthy, J. F., Austin, K. L., Greden, J. F., Young, E. A., & Blow, F. C. (2006). What Happened to Lithium? Antidepressant Augmentation in Clinical Settings: American Journal of Psychiatry Vol 163(7) Jul 2006, 1219-1225.
  • van den Broek, W. W., Birkenhager, T. K., Mulder, P. G. H., Bruijn, J. A., & Moleman, P. (2006). Imipramine Is Effective in Preventing Relapse in Electroconvulsive Therapy-Responsive Depressed Inpatients With Prior Pharmacotherapy Treatment Failure: A Randomized, Placebo-Controlled Trial: Journal of Clinical Psychiatry Vol 67(2) Feb 2006, 263-268.
  • van den Hoofdakker, R. H., Gordijn, M. C. M., & Kasper, S. (1994). Sleep deprivation in refractory depression. Oxford, England: John Wiley & Sons.
  • Vandoolaeghe, E., Maes, M., Vandevyvere, J., & Neels, H. (1997). Hypothalamic-pituitary-thyroid-axis function in treatment resistant depression: Journal of Affective Disorders Vol 43(2) Apr 1997, 143-150.
  • Vanelle, J. M., Loo, H., Galinowski, A., de Carvalho, W., & et al. (1994). Maintenance ECT in intractable manic-depressive disorders: Convulsive Therapy Vol 10(3) Sep 1994, 195-205.
  • Vergouwen, A. C. (1999). Continuation and maintenance electroconvulsive therapy: Tijdschrift voor Psychiatrie Vol 41(3) 1999, 143-149.
  • Viinamaki, H., Haatainen, K., Honkalampi, K., Tanskanen, A., Koivumaa-Honkanen, H., Antikainen, R., et al. (2006). Which factors are important predictors of non-recovery from major depression? A 2-year prospective observational study: Nordic Journal of Psychiatry Vol 60(5) Oct 2006, 410-416.
  • Vinar, O., & Vinarova, E. (1997). Tianeptine helps depressed patients resistant to serotonin function enhancing drugs: Homeostasis in Health and Disease Vol 38(4) Sep 1997, 170-172.
  • Vink, J., Nolen, W. A., & Verbraak, M. (1994). Is moclobemide an alternative for tranylcypromine in treatment-resistant depression? Some experiences: Tijdschrift voor Psychiatrie Vol 36(9) 1994, 639-646.
  • Wada, T., Kanno, M., Aoshima, T., & Otani, K. (2001). Dose-dependent augmentation effect of bromocriptine in a case with refractory depression: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 25(2) Feb 2001, 457-462.
  • Wan, D. D. C., Kundhur, D., Solomons, K., Yatham, L. N., & Lam, R. W. (2003). Mirtazapine for treatment-resistant depression: A preliminary report: Journal of Psychiatry & Neuroscience Vol 28(1) Jan 2003, 55-59.
  • Warnell, R. L., & Elahi, N. (2007). Introduction of vagus nerve stimulation into a maintenance electroconvulsive therapy regimen: A case study and cost analysis: Journal of ECT Vol 23(2) Jun 2007, 114-119.
  • Weintraub, D. (2001). Nortriptyline in geriatric depression resistant to serotonin reuptake inhibitors: Case series: Journal of Geriatric Psychiatry and Neurology Vol 14(1) Spr 2001, 28-32.
  • Weizman, R., Karp, L., Dar, D. E., Butin, B., & et al. (1996). Electroconvulsive therapy down-regulates platelet peripheral-type benzodiazepine receptors in medication-resistant major depressed patients: Biological Psychiatry Vol 40(3) Aug 1996, 221-224.
  • Wetterling, T., Michels, R., & Dilling, H. (1998). Electroconvulsive therapy in therapy resistant depression in old age: Nervenarzt Vol 69(7) Jul 1998, 617-621.
  • Wiethoff, K., Bauer, M., Baghai, T., Heinz, A., & Adli, M. (2005). Algorithms in the treatment of depression--The German Algorithm Project: Nervenheilkunde: Zeitschrift fur interdisziplinaere Fortbildung Vol 24(5) 2005, 381-387.
  • Wijkstra, J., Algra, A., & Nolen, W. A. (2002). Relapse prevention of depression with continuation of electroconvulsive therapy: Tijdschrift voor Psychiatrie Vol 44(1) 2002, 7-18.
  • Wijkstra, J., Nolen, W. A., Algra, A., van Vliet, I. M., & Kahn, R. S. (2000). Relapse prevention in major depressive disorder after successful ECT: A literature review and a naturalistic case series: Acta Psychiatrica Scandinavica Vol 102(6) Dec 2000, 454-460.
  • Wilhelm, K., Mitchell, P., Boyce, P., Hickie, I., & et al. (1994). Treatment resistant depression in an Australian context: I. The utility of the term and approaches to management: Australian and New Zealand Journal of Psychiatry Vol 28(1) Mar 1994, 14-22.
  • Wilhelm, K., Mitchell, P., Sengoz, A., Hickie, I., & et al. (1994). Treatment resistant depression in an Australian context: II. Outcome of a series of patients: Australian and New Zealand Journal of Psychiatry Vol 28(1) Mar 1994, 23-33.
  • Wolf, J., Fiedler, U., Anghelescu, I., & Schwertfeger, N. (2006). Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil: Journal of Clinical Psychiatry Vol 67(11) Nov 2006, 1817.
  • Wright, J. H. (2003). A 25-year-old man with chronic severe depression: Psychiatric Annals Vol 33(9) Sep 2003, 552-554.
  • Wright, J. H. (2003). Cognitive Behavior Therapy for Chronic Depression: Combined treatment may succeed when pharmacologic monotherapy fails: Psychiatric Annals Vol 33(12) Dec 2003, 777-784.
  • Yamamoto, Y., Isogawa, K., Akiyoshi, J., Katsuragi, S., Kono, Y., Furuta, M., et al. (1997). Factors in resistance to antidepressant treatment for major depressive disorder: Seishin Igaku (Clinical Psychiatry) Vol 39(10) Oct 1997, 1083-1087.
  • Yang, X. (2004). Part one. The pharmacogenetics of treatment resistant depression. Part two. DNA interaction and photocleavage by di- and tetracationic intercalants. Dissertation Abstracts International: Section B: The Sciences and Engineering.
  • Yasmin, S., Carpenter, L. L., Leon, Z., Siniscalchi, J. M., & Price, L. H. (2001). Adjunctive gabapentin in treatment-resistant depression: A retrospective chart review: Journal of Affective Disorders Vol 63(1-3) Mar 2001, 243-247.
  • Yatham, L., Calabrese, J. R., & Kusumakar, V. (2003). Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options: Bipolar Disorders Vol 5(2) Apr 2003, 85-97.
  • Yatham, L. N., Kusumakar, V., & Kutcher, S. P. (2002). Treatment of bipolar depression. New York, NY: Brunner-Routledge.
  • Yoshida, K., Sugawara, Y., & Higuchi, H. (2006). Dramatic Remission of Treatment-resistant Depression after the Cessation of Tricyclic Antidepressants: A Case Report: Pharmacopsychiatry Vol 39(3) May 2006, 114.
  • Yukimasa, T., Yoshimura, R., Tamagawa, A., Uozumi, T., Shinkai, K., Ueda, N., et al. (2006). High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors: Pharmacopsychiatry Vol 39(2) Mar 2006, 52-59.
  • Zajecka, J., & Goldstein, C. (2005). Combining and Augmenting: Choosing the Right Therapies for Treatment-resistant Depression: Psychiatric Annals Vol 35(12) Dec 2005, 994-1000.
  • Zajecka, J. M., Jeffriess, H., & Fawcett, J. (1995). The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis: Journal of Clinical Psychiatry Vol 56(8) Aug 1995, 338-343.
  • Zanardini, R., Gazzoli, A., Ventriglia, M., Perez, J., Bignotti, S., Rossini, P. M., et al. (2006). Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients: Journal of Affective Disorders Vol 91(1) May 2006, 83-86.
  • Zarate, C. A., Jr., Charney, D. S., & Manji, H. K. (2007). In reply: "Searching for rational anti-N-methyl-D-aspartate treatment for depression." Archives of General Psychiatry Vol 64(9) Sep 2007, 1100-1101.
  • Zarate, C. A., Jr., Singh, J., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al. (2006). A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression: Archives of General Psychiatry Vol 63(8) Aug 2006, 856-864.
  • Zheng, X. M. (2000). Regional cerebral blood flow changes in drug-resistant depressed patients following treatment with transcranial magnetic stimulation: A statistical parametric mapping analysis: Psychiatry Research: Neuroimaging Vol 100(2) Dec 2000, 75-80.
  • Zill, P., Baghai, T. C., Zwanzger, P., Schule, C., Minov, C., Riedel, M., et al. (2000). Evidence for an association between a G-protein beta 3-gene variant with depression and response to antidepressant treatment: Neuroreport: For Rapid Communication of Neuroscience Research Vol 11(9) Jun 2000, 1893-1897.
  • Zullino, D., Preisig, M., & Baumann, P. (2001). Lithium augmentation in venlafaxine-refractory depression: Journal of Clinical Psychopharmacology Vol 21(2) Apr 2001, 242-243.